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1. Introduction  
The term GMP was introduced to regulate manufacturing and packaging operations in the 
pharmaceutical company. Until the mid-1960s, operating procedures for the manufacture of 
drugs consisted of formulae and the basic methods of making products. Written procedures 
were often concise and often relied on the individual operator’s skill and experience. As 
batches of medicines increased in number and size, the operating procedures were 
inadequate to produce consistent and reliable products. Much attention had focused on the 
purity of medicinal substances. Pharmacopoeias and codices specified formulae for mixtures 
and other preparation, but gave little detailed information on the methods of preparation. 
The factors affecting processing and packaging procedures were becoming more apparent 
and the need for appropriate guidelines was evident (Lund, 1994).  
The Medicines Inspectorate of the Department of Health and Social Security of England, in 
consultation with other interested bodies compiled the guide to GMP also known as the 
Orange Guide. The first edition of the guide was published in 1971, before any formal 
inspections of drug manufacturers had been carried out under the Medicines Act. It was a 
relatively light volume of 20 pages, and was reissued as a third impression in 1972, with the 
addition of a 2-page appendix on sterile medicinal products. Because of the color of its 
cover, it became known as the Orange Guide. The guide was therefore written at a time 
when the nature, extent, and special problems of the manufacturer of drugs were not 
completely known. A second, more substantial edition (52 pages, including five appendices) 
was published in 1977. A third edition (110 pages, five appendices) was published in 1983 
(Lund, 1994). Subsequently, the 2002 edition of Rules and Guidance for Pharmaceutical 
Manufacturers and Distributors, commonly known as the 'Orange Guide', was published 
with many changes and additions to the detailed European Community guidelines on 
GMP.  The Medicines and Healthcare products Regulatory Agency (MHRA) has published 
new edition of the Orange Guide in 2007. 
In United States, the first GMP regulations were issued in 1963 and described the GMP to be 
followed in the manufacture, packaging, and storage of finished pharmaceutical products. 
GMP regulations were developed by the US FDA and issued the United States CFR Chapter 
21 in 1978. The regulations were similar in concept to the Orange Guide, but were 
enforceable by law whereas the UK guide was advisory. US congress passed the Federal 
Ani-tempering Act in 1983, making it a crime to tamper with packaged consumer products. 
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In the 1980s, US FDA began publishing series of guidance documents that have had a major 
effect on our interpretation of current GMP (cGMP). A “Guide to Inspection of 
Computerized Systems in Drug Processing” was published in 1983 and “Guideline on 
General Principles of Process Validation” was published in 1987. In 1992 the congress 
passed the General Drug Enforcement Act.  In March 1997, the US FDA issued 21 CFR Part 
11 which dealt with the use of electronic records and signatures. In 2000, US FDA 
introduced a guidance document on the incorporation of risk management into device 
development (Nally, 2007).  
In August 2002, the US FDA announced a new initiative, Pharmaceutical cGMPs for the 21st 
Century—A Risk Based Approach. The September 2004 final report summarized the 
significant changes in the development and implementation of a new operational 
framework based on quality system and risk management approaches (Nally, 1998). Also in 
September 2004, the publication of the Process Analytical Technology (PAT) initiative 
guidance document supported innovation and efficiency in pharmaceutical manufacturing 
with a risk management foundation (USFDA, 2004).  
The first World Health Organization (WHO) draft on GMP was prepared at the request of 
the twentieth World Health Assembly (resolution WHA 20.34) in 1967 by a group of 
consultants. The revised text was discussed by the WHO Expert Committee on 
Specifications for Pharmaceutical Preparations in 1968 and published as an annex to its 
twenty-second report. The text was further reproduced in 1971 in the Supplement to the 
second edition of The International Pharmacopoeia (WHOTRS823, 1992). 
Text on GMP was accepted as an integral part of WHO certification scheme on the quality of 
pharmaceutical products moving in international market by WHA in 1969. The WHA, in 
resolution No.WHA28.65 accepted the revised version of both the GMPs and the 
certification scheme in 1975. The revised text is published in Thirty-second Report of WHO 
Expert Committee on Specifications for Pharmaceutical Preparations: WHO TRS 823 in 1992 
(Sharma, 1995). In 2003, WHO TRS 908 had revised the content of GMP in its Annex 4: Good 
Manufacturing Practices for pharmaceutical products: main principles (WHO TRS 908, 
2003). Recently WHO TRS 961 has published the updated contents on GMP in Annex 3: 
WHO good manufacturing practices: main principles for pharmaceutical products (WHO 
TRS 961, 2011).  
2. Importance of GMP 
In the United States the Center for Drug Evaluation and Research (CDER) promotes and 
protects public health by assuring that safe and effective drugs are available to Americans. 
There exits different types of risk with medicines (Figure 1), one of which is a preventable 
adverse event, which can be caused by different reasons. One of the reasons for this event 
can be a product quality defect. This risk can be avoided by effective implementation of 
GMP (US FDA CDER, 2001). 
Friedrich Nietzsche once said, “If you know the why for living, you can endure any how.” 
Everyone in our industry should know the story of how the GMP has come in practice. Most 
requirements were put in place as responses to tragic circumstances and to prevent future 
tragedies (Immel, 2005).  
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Fig. 1. Sources of Risk from Drug Products (Source: USFDA CDER 2001) 
Sulfanilamide, a drug used to treat Streptococcal infections, had been shown to have 
dramatic curative effects and had been used safely for some time in tablet and powder form. 
In June 1937, however, a salesman for the S.E. Massengill Co., in Bristol, Tenn., reported a 
demand in the southern US states for the drug in liquid form. The company's chief chemist 
and pharmacist, Harold Cole Watkins, experimented and found that Sulfanilamide would 
dissolve in diethylene glycol. The company control laboratory tested the mixture for flavor, 
appearance, and fragrance and found it satisfactory. Immediately, the company 
compounded a quantity of Sulfanilamide elixir and sent shipments-all over the country 
(USA). The new formulation had not been tested for toxicity. At the time the food and drugs 
law did not require that safety studies be done on new drugs.  
Because no pharmacological studies had been done on the new Sulfanilamide preparation, 
Watkins failed to note one characteristic of the solution. Diethylene glycol, a chemical 
normally used as antifreeze, is a deadly poison. The use of an oral Sulfanilamide elixir has 
caused the death of 107 people, many of them children before the problem was discovered. 
In response, US Congress passed the Federal Food, Drug and Cosmetic (FD&C) Act of 1938. 
For the first time, companies were required to prove that their products were safe before 
marketing them. 
During 1960’s Thalidomide was marketed in Europe as a sleeping pill and to treat morning 
sickness. When regulatory agencies gave permission to sell the drug for those indications, 
they knew nothing of its serious side effects. It turned out to be teratogenic: It caused serious 
deformities in developing fetuses. Children whose mothers took Thalidomide in the first 
trimester were born with severely deformed arms and legs. An estimated 10,000 cases of 
infant deformities in Europe were linked to Thalidomide use. Thalidomide galvanized 
public opinion. Two legislators, Kefauver and Harris, pushed more stringent legislation 
through US Congress that required companies to test not only to ensure that products were 
safe, but that they were efficacious for their intended uses (Immel, 2005). 
Sharp, (1991) reported that at least 109 infants in Nigeria have died due to failure to follow 
GMP. This was caused due to the supply of mislabeled ethylene glycol as propylene glycol. 
This mislabeled material was then supplied to a pharmaceutical manufacturer. The 
manufacturer failed to perform adequate incoming quality control identification and 
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potency tests and final product evaluation did not pick up the problem. This has resulted 
due to failure in following GMP norms in manufacturing drugs. The effective 
implementation of GMP would prevent this mistake. 
There was an incident of the outbreak of diethylene glycol poisoning that occurred in Haiti 
from November 1995 to June 1996 due to contamination of glycerol with diethylene glycol 
used in the preparation of paracetamol syrup. The incident led to some 89 deaths of children 
from Kidney failure. This was notified by the WHO through its newsletter no.10th Oct. 1996. 
The cause of fetal incident once again became the same deadly poisonous chemical 
diethylene glycol which casued the death of 107 people way back in 1937. The outbreak in 
Haiti emphasizes the need for pharmaceutical manufacturers’ world wide to be aware of 
possible contamination of glycerol and other raw materials with diethylene glycol and to 
use appropriate quality control measure to identify and prevent potential contamination. 
This also has strengthened the enforcement of GMP guidelines to ensure safety and efficacy 
of the pharmaceutical products.  
Effective implementation of GMP would also provide the cost benefit to the manufacturers, 
by avoiding the cost of failures such as cost of waste, of rework, of recall, of consumer 
compensation, of company reputation, and of regulatory action suspending operations. 
3. Good Manufacturing Practices (GMP) guidelines  
GMP is a production and testing practice that helps to ensure a quality product. Many 
countries have legislated that pharmaceutical and medical device companies must follow 
GMP procedures, and have created their own GMP guidelines that correspond with their 
legislation. Basic concepts of all of these guidelines remain more or less similar to the 
ultimate goals of safeguarding the health of the patient as well as producing good quality 
medicine, medical devices or active pharmaceutical products 
GMP guidelines are not prescriptive instructions on how to manufacture products. They are 
a series of general principles that must be observed during manufacturing. When a 
company is setting up its quality program and manufacturing process, there may be many 
ways it can fulfill GMP requirements. It is the company's responsibility to determine the 
most effective and efficient quality process. The formalization of GMP commenced in the 
1960s and they are now in effect in over 100 countries ranging from Afghanistan to 
Zimbabwe. Although many countries have developed local requirements, many also rely on 
the World Health Organization recommended GMP (WHO GMP) for pharmaceutical 
products. Regional requirements have also appeared with application to several countries. 
Examples of these include the following. 
a. Pharmaceutical Inspection Convention (PIC)—guide to GMP for pharmaceutical 
products—Australia, Austria, Belgium, Canada, Denmark, Finland, France, Hungary, 
Ireland, Italy, Latvia, Liechtenstein, Malaysia, The Netherlands, Norway, Poland, 
Portugal, Romania, Singapore, Slovak Republic, Spain, Sweden, Switzerland, and the 
United Kingdom. 
b. Association of South-East Asia Nations (ASEAN)—GMP: general guidelines—Brunei 
Darussalaam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, 
Singapore, Thailand, and Vietnam. 
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c. European Economic Community (EEC)—guide to GMP for medicinal products—
Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, 
Luxembourg, the Netherlands, Portugal, Spain, Sweden, and the United Kingdom. 
The above mentioned guidelines are similar in design and content and model more of a 
quality management approach or principle when compared with product testing and 
control more prevalent in the U.S. cGMP. Over the years, these regulations/guides have also 
been supplemented by descriptive guidelines providing additional information on specific 
topics. In general, GMP have been issued as guides to the achievement of consistent product 
quality, with interpretation and individual variations being accepted. GMP are enforced in 
the United States by the US FDA, under Section 501(B) of the 1938 Food, Drug, and 
Cosmetic Act (21 USCS § 351). The regulations use the phrase "current good manufacturing 
practices" (cGMP) to describe these guidelines.  
The World Health Organization (WHO) version of GMP is used by pharmaceutical 
regulators and the pharmaceutical industry in over one hundred countries worldwide, 
primarily in the developing world including country like Nepal. The European Union's 
GMP (EU-GMP) enforces similar requirements to WHO GMP, as does the Food and Drug 
Administration's version in the US. Similar GMPs are used in other countries, with 
Australia, Canada, Japan, Singapore and others having highly developed/sophisticated 
GMP requirements. In the United Kingdom, the Medicines Act (1968) covers most aspects of 
GMP in what is commonly referred to as "The Orange Guide", which is officially known as 
Rules and Guidance for Pharmaceutical Manufacturers and Distributors.  
In general, GMP inspections are performed by national regulatory agencies. GMP 
inspections are performed in the United Kingdom by the Medicines and Healthcare 
Products Regulatory Agency (MHRA); in the Republic of Korea (South Korea) by the Korea 
Food & Drug Administration (KFDA); in Australia by the Therapeutical Goods 
Administration (TGA); in South Africa by the Medicines Control Council (MCC); in Brazil 
by the Agência Nacional de Vigilância Sanitária (National Health Surveillance Agency 
Brazil) (ANVISA). In India GMP inspections are carried out by state Food and Drug 
Administration (FDA) and these FDA report to Central Drugs Standard Control 
Organization: in Nepal, GMP inspections are carried out by the Department of Drug 
Administration (DDA), and in Pakistan by the Ministry of Health.  Nigeria has National 
Agency for Food and Drug Administration and Control (NAFDAC). Each of the 
inspectorates carry out routine GMP inspections to ensure that drug products are produced 
safely and correctly; additionally, many countries perform pre-approval inspections (PAI) 
for GMP compliance prior to the approval of a new drug for marketing (Wikipedia, 2012a). 
4. Components of GMP 
GMP requires that the manufacturing process is fully defined before being initiated and all 
the necessary facilities are provided. In practice, personnel must be adequately trained, 
suitable premises and equipment used, correct materials used, approved procedures 
adopted, suitable storage and transport facilities available, and appropriate records made. 
The essential components of GMP are summarized in Figure 2 (Lund, 1994). 
The manufacturing premises of good design and regularly monitored is the most important 
component. There should be quality control of finished product, raw materials and 
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packaging materials. The equipment of good design is to be considered and all the 
equipments are required to be maintained properly. There should be a correct choice of 
cleaning equipment. The staffs should be trained well and should be wearing protective 
clothing while on work. There should be written procedures for carrying out the operations. 
 
Fig. 2. Components of Good Manufacturing Practice (Source: Lund, 1994) 
WHO Expert Committee on Specifications for Pharmaceutical Preparations had published 
the Forty-fifth Report of WHO TRS 961 in 2011. The committee reviewed the revision of the 
GMP text in the light of comments received from interested parties and brought out the 
basic guidelines on GMP in an Annex 3 under the title “WHO good manufacturing practice: 
main principles for pharmaceutical products.”  
Among other feedback which was discussed during the consultation on WHO guidelines for 
medicines quality assurance, quality control laboratories and transfer of technology on 27–
31 July 2009, the need was identified to incorporate a new section on “Product quality 
review” under Chapter 1: “Quality assurance”. In addition, several updates were suggested 
to further enhance the guidelines and include the concept of risk management, replacing 
“drugs” by the term “medicines” and newly introduce the concept of a “quality unit”. 
Quality unit is an organizational unit independent of production which fulfils both quality 
assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate 
QA and QC units or a single individual or group, depending upon the size and structure of 
the organization. 
This has highlighted the different requirements of GMP as “Quality management in the 
medicines industry: philosophy and essential elements”. The essential elements described in 
detail includes; Quality assurance, Good manufacturing practices for pharmaceutical 
products,  Sanitation and hygiene, Qualification and validation, Complaints, Product recalls, 
Contract production and analysis, Self-inspection, quality audits and supplier’s audits and 
approval, Personnel, Training, Personal hygiene, Premises, Equipment, Materials, 
Documentation, Good practices in production and Good practices in quality control 
(WHOTRS 961, 2011).   
Volume 4 of "The rules governing medicinal products in the European Union" contains 
guidance for the interpretation of the principles and guidelines of good manufacturing 
practices for medicinal products for human and veterinary use. Its 1998 edition contains 
nine chapters describing Quality management, Personnel, Premises and Equipment, 
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Documentation, Production, Quality control, Contract manufacturing and analysis, 
Complaints and Product recall and Self Inspection as basic requirements of GMP with 14 
annexes. Currently the guide is presented in three parts and supplemented with a series of 
annexes. Part I covers basic requirements for medicinal products, Part II covers basic 
requirements for active substances used as starting materials and Part III contains GMP 
related documents, which clarify the regulatory expectations (EudraLex, 2012). 
Pharmaceutical inspection convention/Pharmaceutical Inspection Co-operation Scheme 
(PIC/S) had published PE 009-2 Guide to GMP for medicinal products in 2004. In order to 
further facilitate the removal of barriers to trade in medicinal products, to promote 
uniformity in licensing decisions and to ensure the maintaining of high standards of quality 
assurance in the development, manufacture and control of medicinal products throughout 
Europe, it was agreed to harmonize the rules of GMP applied under Pharmaceutical 
Inspection Convention (PIC) and the Pharmaceutical Inspection Co-operation Scheme 
(PIC/S) to those of the EU Guide to Good Manufacturing Practice for Medicinal Products 
and its Annexes. The guide contains nine chapters describing Quality management, 
Personnel, Premises and Equipment, Documentation, Production, Quality control, Contract 
manufacturing and analysis, Complaints and Product recall and Self Inspection with 18 
annexes.   
US FDA ensures the quality of drug products by carefully monitoring drug manufacturers' 
compliance with its cGMP regulations.  Section 21 of the CFR contains most regulations 
pertaining to food and drugs.  The regulations document the actions of drug sponsors that 
are required under Federal law. 21 CFR Part 210.  cGMP in manufacturing processing, 
packing, or holding of drugs. 21 CFR Part 211.  cGMP for finished pharmaceuticals. The CFR 
21 part 211 dealing with cGMP for finished pharmaceuticals consists of Subparts A to K 
describing different components as General Provisions, Organization and Personnel, 
Building and Facilities, Equipment, Control of Components and Drug Product Containers 
and Closures, Production and Process Controls, Packaging and Labeling Control, Holding 
and Distribution, Laboratory Controls, Records and Reports and Returned and Salvaged 
Drug Products (Revised as of April 1, 2011). 
The ASEAN GMP general guidelines have covered following elements such as Personnel, 
Premises, Sanitation, Equipment, Starting Materials, Production, Quality Control, Self 
Inspection, Handling of product complaint, product recall and returned drug products and 
Documentation, (ASEAN, 2000).   
Indian schedule M for GMP and requirements of premises, plant and equipment for 
pharmaceutical products consists of Part I mentioning GMP for Premises and Materials. The 
Part I includes General requirements, Warehousing area, Production area, Ancillary area, 
Quality control area, Personnel, Health, clothing and sanitation of workers, Manufacturing 
operations and controls, Sanitation in the manufacturing premises, Raw materials, 
Equipment, Documentation and Records, Labels and other printed materials, Quality 
assurance, Self inspection and quality audit, Quality control system, Specification, Master 
formula records, Packing records, Batch packaging records, Batch processing records, 
Standard operating procedures (SOPs) and records, Reference samples, Reprocessing and 
recoveries, Distribution records, Validation and process validation, Product recalls, 
Complaints and adverse reactions and Site-master file. Part I-A to part I-E mentions about 
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the specific requirements for manufacture of different products and Part I-F mentions about 
the specific requirements of premises, plant and materials for manufacture of active 
pharmaceutical ingredients (bulk drugs). Part II describes the Requirement of plant and 
equipments for various dosage forms (Schedule M). 
Worldwide, there are now around 30 different official national and super national 
statements on GMP. These have been published variously as guides, codes and regulations 
and of the 30 or so of them, two stand out as being the most influential and most frequently 
referenced: The United States Current Good Manufacturing Practice (cGMP) Regulations 
and the European Commission’s “Good Manufacturing Practices for Medicinal Products for 
Human and Veterinary Use”. Thirdly the WHO version of GMP is used by the 
pharmaceutical regulators and the pharmaceutical industry in over 100 countries 
worldwide, primarily in the developing world (Nally, 2007). 
 
Fig.  3. Consolidated Components of Good Manufacturing Practices  
While reviewing all the above documents, it is realized that most of the components 
identified for GMP aspects are similar in all the guidelines and publications. Based on the 
above discussion, the following components of GMP would cover all the requirements made 
by different authorities and also satisfy the WHO GMP guidelines for drug manufacturing: 
Quality management, Quality assurance, Good manufacturing practices for medicinal 
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products, Quality control, Sanitation and hygiene, Qualification and validation, Complaints 
and product recalls, Contract production and analysis, Self-inspection, quality audits and 
supplier’s audits and approval, Personnel training and personal hygiene, Premises, 
Equipment, Materials, Documentation and Holding and Distribution. These consolidated 
components shown in Figure 3 are dealt one by one independently with reference to above 
mentioned GMP statements.  
4.1 Quality management 
The holder of a Manufacturing Authorization must manufacture medicinal products so as to 
ensure that they are fit for their intended use, comply with the requirements of the 
Marketing Authorization and do not place patients at risk due to inadequate safety, quality 
or efficacy. The attainment of this quality objective is the responsibility of senior 
management and requires the participation and commitment by staff in many different 
departments and at all levels within the company, by the company’s suppliers and by the 
distributors (EudraLex, 2012). In the pharmaceutical industry at large, quality management 
is usually defined as the aspect of management function that determines and implements 
the “quality policy”, i.e. the overall intention and direction of an organization regarding 
quality, as formally expressed and authorized by top management (WHOTRS 961, 2011). 
The basic elements of quality management are: an appropriate infrastructure or “quality 
system”, encompassing the organizational structure, procedures, processes and resources; 
and systematic actions necessary to ensure adequate confidence that a product (or service) 
will satisfy given requirements for quality. 
4.2 Quality Assurance (QA) 
QA is a wide-ranging concept, which covers all matters, which individually or collectively 
influence the quality of a product. It is the sum total of the organized arrangements made 
with the objective of ensuring that pharmaceutical products are of the quality required for 
their intended use. QA, therefore, incorporates GMP and other factors such as product 
design and development. 
The system of QA appropriate for the manufacture of pharmaceutical products should 
ensure that: (a) pharmaceutical products are designed and developed in a way that takes 
account of the requirements of GMP and other associated codes such as those of good 
laboratory practice (GLP) and good clinical practice (GCP); (b) production and control 
operations are clearly specified in a written form and GMP requirements are adopted; (c) 
managerial responsibilities are clearly specified in job descriptions; (d) arrangements are 
made for the manufacture, supply and use of the correct starting and packaging materials; 
(e) all necessary controls on starting materials, intermediate products, and bulk products 
and other in-process controls, calibrations, and validations are carried out; (f) the finished 
product is correctly processed and checked, according to the defined procedures; (g) 
pharmaceutical products are not sold or supplied before the authorized persons have 
certified that each production batch has been produced and controlled in accordance with 
the requirements of the marketing authorization and any other regulations relevant to the 
production, control and release of pharmaceutical products; (h) satisfactory arrangements 
exist to ensure, as far as possible, that the pharmaceutical products are stored by the 
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manufacturer, distributed, and subsequently handled so that quality is maintained 
throughout their shelf-life; (i) here is a procedure for self-inspection and/or quality audit 
that regularly appraises the effectiveness and applicability of the QA system; (j) deviations 
are reported, investigated and recorded; (k) there is a system for approving changes that 
may have an impact on product quality; (l) regular evaluations of the quality of 
pharmaceutical products should be conducted with the objective of verifying the 
consistency of the process and ensuring its continuous improvement; and (m) there is a 
system for quality risk management (QRM). 
4.2.1 Product quality review 
Regular periodic or rolling quality reviews of all licensed medicinal products, including 
export-only products, should be conducted with the objective of verifying the consistency of 
the existing process, the appropriateness of current specifications for both starting materials 
and finished product to highlight any trends and to identify product and process 
improvements. Such reviews should normally be conducted and documented annually, 
taking into account previous reviews, and should include at least: (i) a review of starting 
materials including packaging materials used for the product, especially those from new 
sources; (ii) a review of critical in-process controls and finished product results; (iii) a review 
of all batches that failed to meet established specification(s) and their investigation; (iv)  a 
review of all significant deviations or non-conformances, the related investigations, and the 
effectiveness of resultant corrective and preventative actions taken; (v) a review of all 
changes made to the processes or analytical methods; (vi) a review of dossier variations 
submitted, granted or refused; (vii) a review of the results of the stability monitoring 
programme and any adverse trends; (viii) a review of all quality-related returns, complaints 
and recalls and the investigations performed at the time; (ix) a review of adequacy of any 
other previous corrective actions on product process or equipment; (x) for new dossiers and 
variations to the dossiers, a review of post-marketing commitments; (xi) the qualification 
status of relevant equipment and utilities, e.g. heating, ventilation and air-conditioning 
(HVAC), water, or compressed gases; and (xii) a review of technical agreements to ensure 
that they are up to date (WHOTRS 961, 2011). 
4.2.2 Quality Risk Management (QRM) 
QRM is a systematic process for the assessment, control, communication and review of risks 
to the quality of the medicinal product. It can be applied both proactively and 
retrospectively. The quality risk management system should ensure that: 
- the evaluation of the risk to quality is based on scientific knowledge, experience with 
the process and ultimately links to the protection of the patient; and  
- the level of effort, formality and documentation of the QRM process is commensurate 
with the level of risk. 
4.3 Good Manufacturing Practice (GMP) for medicinal products 
GMP is that part of QA which ensures that products are consistently produced and 
controlled to the quality standards appropriate to their intended use and as required by the 
marketing authorizations or product specification.  GMP is aimed primarily at diminishing 
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the risks inherent in any pharmaceutical production. Such risks are essentially of two types: 
cross-contamination (in particular of unexpected contaminants) and mix ups (confusion) 
caused by, for example, false labels being put on containers. 
The basic requirements of GMP are that: (a) all manufacturing processes are clearly defined, 
systematically reviewed in the light of experience, and shown to be capable of consistently 
manufacturing pharmaceutical products of the required quality that comply with their 
specifications; (b) qualification and validation are performed; (c) all necessary resources are 
provided; (d) instructions and procedures are written in clear and unambiguous language, 
specifically applicable to the facilities provided; (e) operators are trained to carry out 
procedures correctly; (f) records are made during manufacture to show that all the steps 
required by the defined procedures and instructions have in fact been taken and that the 
quantity and quality of the product are as expected; any significant deviations are fully 
recorded and investigated; (g) records covering manufacture and distribution, which enable 
the complete history of a batch to be traced, are retained in a comprehensible and accessible 
form; (h) the proper storage and distribution of the products minimizes any risk to their 
quality; (i) a system is available to recall any batch of product from sale or supply; and (j) 
complaints about marketed products are examined, the causes of quality defects 
investigated, and appropriate measures taken in respect of the defective products to prevent 
recurrence (WHOTRS 961, 2011). 
4.4 Quality Control (QC) 
QC is that part of GMP which is concerned with sampling, specifications and testing, and 
with the organization, documentation and release procedures which ensure that the 
necessary and relevant tests are actually carried out and that materials are not released for 
use, nor products released for sale or supply, until their quality has been judged to be 
satisfactory. QC is not confined to laboratory operations, but may be involved in many 
decisions concerning the quality of the product. QC as a whole will also have other duties, 
such as to establish, validate and implement all QC procedures, to evaluate, maintain, and 
store the reference standards for substances, to ensure the correct labeling of containers of 
materials and products, to ensure that the stability of the active pharmaceutical ingredients 
(APIs) and products is monitored, to participate in the investigation of complaints related to 
the quality of the product, and to participate in environmental monitoring. All these 
operations should be carried out in accordance with written procedures and, where 
necessary, recorded (WHOTRS 961, 2011). 
4.5 Sanitation and hygiene 
A high level of sanitation and hygiene should be practiced in every aspect of the 
manufacture of medicine products. The scope of sanitation and hygiene covers personnel, 
premises, equipment and apparatus, production materials and containers, products for 
cleaning and disinfection, and anything that could become a source of contamination to the 
product. Potential sources of contamination should be eliminated through an integrated 
comprehensive programme of sanitation and hygiene. Premises used in the manufacture, 
processing, packing, or holding of a drug product shall be maintained in a clean and 
sanitary condition, Any such building shall be free of infestation by rodents, birds, insects, 
and other vermin (other than laboratory animals). There shall be written procedures 
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assigning responsibility for sanitation and describing in sufficient detail the cleaning 
schedules, methods, equipment, and materials to be used in cleaning the buildings and 
facilities; such written procedures shall be followed. Records should be maintained. 
 
Substance 
Suitable 
Concentration 
Effect on 
Bacteria 
Effect 
on 
Spores 
Effect on 
Vegetative 
Fungi 
Advantages Disadvantages 
Ethanol 70% Good Fair Fair 
Quick acting; 
evaporates 
rapidly, 
leaving no 
residues 
Limited range of 
effect; 
flammable 
Phenols 0.5–3% Excellent Good Excellent 
Broad range of 
effect; 
may be combined 
with surfactants 
Corrosive on some 
surfaces (including 
skin) 
Formaldehyde  Excellent Good Good 
Broad range of 
effect; 
used for “gassing” 
Premises not 
accessible 
during treatment; can 
be 
corrosive; short- and 
long-term human 
toxicity problems 
Isopropanol 70–90% Good Good Good 
Quick acting; 
evaporates, 
leaving 
no residues 
Not the most effective 
Iodine and 
iodophors 
75–150 ppm 
 
Excellent 
Good Excellent 
Quick acting; 
effective in low 
concentration 
Can be corrosive; 
stains 
some surfaces 
Chlorine 
compounds 
(hypochlorite, 
chloramines, 
etc.) 
1–4% 
 
Excellent 
Good Excellent 
Broad range of 
effect 
Corrosive 
Quaternary 
ammonium 
compounds 
1–5% Good Fair Fair 
Some cleaning 
effect; 
odorless 
Limited effect; 
inactivated 
by soap detergents 
Table 1. Disinfectants for Premises — Types and Applications (Source: Sharp, 2005) 
The areas, surfaces, and equipment in and on which products are made must be kept clean. 
Dirt, and the microbes that it can harbor, must not get into or on products. Disinfectants can 
be inactivated by dirt. Dirt (particularly oily or greasy films and protein like matter) can also 
protect microorganisms against the action of disinfectants. So, before disinfection, it is 
important to first clean surfaces. Where gross amounts of dirt are present, it may be 
necessary to first remove most of it by scrubbing. Then surfaces may be cleaned by the 
application of a cleaning agent, followed by rinsing.  
A wide range of substances are used as disinfectants. They may be single substances, like 
alcohols or phenols, and there are a number of commercially available mixtures. It is usually 
best not to make “do it yourself” mixtures. It could be dangerous, and some disinfectants 
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can neutralize each other’s activity. Disinfecting agents vary in the range of their activity 
and in the concentrations at which they are effective. All have their own special advantages 
and disadvantages. Some examples of disinfectants, with their range of effects, etc. are 
shown in Table 1.  Disinfectants should always be used in accordance with instructions and 
at the right dilution (instructions as given either in the supplier’s literature or in company 
procedures). Since some microorganisms can grow readily in dilute disinfectants, dilutions 
of disinfectants should not be stored unless they are sterilized. Otherwise, dilutions should 
be made freshly each time they are needed. It is advisable to use different disinfectants over 
a period of time, on an alternating, or rotating, basis to prevent the development of 
disinfectant-resistant strains of microorganisms.  
4.5.1 Personal hygiene  
All personnel, prior to and during employment, as appropriate, should undergo health 
examinations. Personnel conducting visual inspections should also undergo periodic eye 
examinations. All personnel should be trained in the practices of personal hygiene. Any 
person shown at any time to have an apparent illness or open lesions that may adversely 
affect the quality of products should not be allowed to handle starting materials, packaging 
materials, in-process materials or medicines products until the condition is no longer judged 
to be a risk. Direct contact should be avoided between the operator’s hands and starting 
materials, primary packaging materials and intermediate or bulk product. To ensure 
protection of the product from contamination, personnel should wear clean body coverings 
appropriate to the duties they perform, including appropriate hair covering. To reduce the 
risk of infection through hand contact, the following should be instructed to all operators:  
- Do not touch the product/objects that may come in contact with the product, with 
unprotected hands.  
- Keep the hands well groomed with short, clean nails. Hands must be free of any lesions, 
wounds, cuts, boils, or any other sources of infection. 
- Wrist watches, rings, or other jewelry should not be worn on the job. 
- Hands should be washed before work and as often as the job requires (Figure 4).  
- Protective gloves should be worn when working with open products and when 
handling objects that come in direct contact with the product.  
Smoking, eating, drinking, chewing, and keeping plants, food, drink, smoking material and 
personal medicines should not be permitted in production, laboratory and storage areas. 
Personal hygiene procedures including the use of protective clothing should apply to all 
persons entering production areas, whether they are temporary or full-time employees or 
nonemployees, e.g. contractors’ employees, visitors, senior managers and inspectors. 
4.6 Qualification and validation 
Qualification is an action of proving that any premises, systems and items of equipment 
work correctly and actually lead to the expected results. Validation is defined as the 
establishing of documented evidence which provides a high degree of assurance that a 
planned process will consistently perform according to the intended specified outcomes. 
Validation studies should reinforce GMP and be conducted in accordance with defined 
procedures. Results and conclusions should be recorded. When any new manufacturing 
formula or method of preparation is adopted, steps should be taken to demonstrate its  
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Fig. 4.  Seven Steps to Effective Hand Washing  
suitability for routine processing. The defined process, using the materials and equipment 
specified, should be shown to yield a product consistently of the required quality. 
Significant amendments to the manufacturing process, including any change in equipment 
or materials, which may affect product quality and/or the reproducibility of the process, 
should be validated. Processes and procedures should undergo periodic critical revalidation 
to ensure that they remain capable of achieving the intended results (PIC/S, 2004). Every 
step of the process of manufacture of a medicinal product must be shown to perform as 
intended. Once the system or process has been validated, it is expected that it remains in 
control, provided no changes are made. In the event that modifications are made, or 
problems occur, or equipment is replaced or relocated, revalidation is performed. The 
validity of systems/equipment/tests/processes can be established by prospective, 
concurrent or retrospective studies. 
Qualification and validation should establish and provide documentary evidence that: (a) 
the premises, supporting utilities, equipment and processes have been designed in 
accordance with the requirements for GMP (design qualification or DQ); (b) the premises, 
supporting utilities and equipment have been built and installed in compliance with their 
design specifications (installation qualification or IQ); (c)  the premises, supporting utilities 
and equipment operate in accordance with their design specifications (operational 
qualification or OQ); and (d) a specific process will consistently produce a product meeting 
its predetermined specifications and quality attributes (process validation or PV, also called 
performance qualification or PQ). 
 
1. Palm to 
palm 
 
2. Right palm over 
left dorsum and 
left palm over 
right dorsum 
3. Palm to 
palm fingers 
interlaced 
 
5. Rotational rubbing 
of right thumb clasped 
in left palm and vice 
versa 
 
6. Rotational rubbing, 
backwards and forwards with 
clasped fingers of right hand 
in left palm and vice versa 
 
4. Backs of fingers to 
opposing palms with 
fingers interlocked 
 
7. Rotational rubbing 
of left wrist in with 
right palm and vice 
versa 
Pharma manufacturing personnel should be aware that hand washing is not as
effective if rings, wrist watches, nail polish or false nails (including gel/acrylic nails)
are worn and therefore there are NOT PERMITTED within the clean room area 
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4.6.1 Validation protocols and validation master plan 
A protocol is a written set of instructions broader in scope than a Standard Operating 
Procedure (SOP). A protocol describes the details of a comprehensive planned study to 
investigate the consistent operation of new system/equipment, a new procedure, or the 
acceptability of a new process before it is implemented. The Validation Master Plan (VMP) 
is a high-level document which establishes an umbrella validation plan for the entire project, 
and is used as guidance by the project team for resource and technical planning (also 
referred to as master qualification plan). VMP describes which equipment, systems, 
methods and processes will be validated and when they will be validated. The document 
should provide the format required for each particular validation document (Installation 
Qualification, Operational Qualification and Performance Qualification for equipment and 
systems; Process Validation; Analytical Assay Validation), and indicate what information is 
to be contained within each document.  
4.6.2 Analytical procedures and methods validation 
Method validation is the process used to confirm that the analytical procedure employed for 
a specific test is suitable for its intended use. Results from method validation can be used to 
judge the quality, reliability and consistency of analytical results; it is an integral part of any 
good analytical practice.  Analytical methods need to be validated or revalidated before 
their introduction into routine use; whenever the conditions change for which the method 
has been validated (e.g., an instrument with different characteristics or samples with a 
different matrix); and whenever the method is changed and the change is outside the 
original scope of the method (Huber, 2012).  
The parameters for method validation have been defined in different working groups of 
national and international committees and are described in the literature. Unfortunately, 
some of the definitions vary between the different organizations. An attempt at 
harmonization was made for pharmaceutical applications through the ICH, where 
representatives from the industry and regulatory agencies from the United States, Europe 
and Japan defined parameters, requirements and, to some extent, methodology for 
analytical methods validation. The parameters, as defined by the ICH and by other 
organizations and authors, are summarized in Table 2.   
 
Selectivity and Specificity (1,2) and  Precision (1,2) and reproducibility (3) 
Accuracy (1,2) and Recovery Linearity (1,2) 
Range (1,2) Limit of detection (1,2) 
Limit of quantitation (1,2) Robustness (2,3) 
Ruggedness (2)  
(1) Included in ICH, (2) Included in USP,  (3) Terminology included in ICH publication but not part of 
required parameters  
Table 2. Possible Analytical Parameters for Method Validation (Source: Huber, 2012) 
4.7 Complaints and product recalls 
QA and GMP are about preventing errors. However, in this imperfect universe there is no 
such thing as an infallibly perfect system, and an essential feature of any QA system is a 
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plan for dealing with complaints, or reports of faulty products, if they do occur. A 
requirement to cover this occurs in all notable GMP guidelines. Complaints received from 
consumers, professionals, and the trade serves as a primary means of obtaining feedback 
about product quality after distribution. It is necessary, therefore, that each complaint or 
inquiry be evaluated by knowledgeable and responsible personnel (Nally, 2007). 
The records of production, packaging, and distribution of drug and the retained samples 
provide the basis for assessing the validity and seriousness of the alleged deviations that 
precipitated the complaint. The complaint file itself also plays an important role in 
determining whether any other similar complaints have been received on the lot in question, 
or on any other lots of the same product. The evaluation of complaints serves several 
valuable purposes. First, there is the urgent need to confirm whether consumers are 
potentially at risk and to initiate any appropriate action. A second value is the review of the 
product and its production process to establish whether any modifications are required. 
Third is the need to rapidly respond to the customer, thereby attempting to maintain 
confidence in the product and company. 
Manufacturers should have a written recall procedure, with nominated persons responsible 
for implementing it as necessary, within, or outside of, normal working hours. Distribution 
records should be maintained, which will facilitate effective recall, and the written 
procedure should include emergency and off-hours contacts and telephone numbers (Sharp, 
2005). 
The complaints and defect report procedure is intended to be operated in conjunction with a 
“COMPLAINT/DEFECT REPORT” record (Figure 5), a copy of which, as is indicated, 
should form part of the SOP. Copies of this report form should be provided to all persons in 
the organization who may possibly be the first recipients of a complaint. They should be 
trained in its use and in the crucial importance of taking all such reports very seriously.  As 
the complaints and defect report SOP indicates, if the complaints (etc.) procedure leads to a 
conclusion to recall (or freeze), then the recall (or freeze) procedure must be implemented. It 
is vital that this SOP is kept up to date, particularly in regard to internal and external names, 
addresses, and phone numbers, and that it is regularly shown (by “dummy runs”) to be 
operable at any time. (The need to urgently recall does not arise only between 08.00 hours to 
17.00 hours, Monday through Friday.)  
As explained above the extent of recall, if required to do so depends on the distribution 
channel and record system of the company. In case of developed countries with well 
developed system of distribution records starting form the manufacturer up to the end user 
level, the recall procedure would be possible up to the end user. In such countries, the 
effective recall can protect patients, in cases of the product defects which may have severe 
adverse effect on the patient from use of the product if it is not recalled. However, the 
scenario of such recall procedure is very much alarming in case of developing countries 
where the distribution records of products are not traceable up to the end user, which needs 
to be recalled. Majority of the cases the distribution records are maintained up to the 
wholesaler, and/or retailer’s level.  In this scenario for serious cases, the recall procedure 
simply fails to achieve its goal to protect the end user form the impact of the effect. This 
needs to be strengthened by developing stringent regulatory requirements to have proper 
distribution record available up to the patient level for effective recall at the time of need. 
Otherwise the system of effective recall remains as SOP only. 
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Fig. 5. Complaint/Defect Report Record (Source: Sharp, 2005) 
4.8 Contract production and analysis 
The global industry is changing its shape through rationalization, mergers and acquisitions.  
Companies are increasingly considering the use of other manufacturers to produce or 
manufacture their products. Companies are also finding that they do not have the 
technology or expertise to manufacture certain new special dosage forms.  In some cases, 
financial targets mean that companies are not using manufacturing as a core business 
process.  This means that the importance of contract manufacturing and testing of products 
 
         Page 1 of 1 
1. Date Complaint/Report received ………………..  Time ……….. 
2. Received by ………………………………………. 
3. Received from: 
Name ………………………………….. 
Address: 
Telephone number ………………….. 
Fax number …………………………... 
e-mail …………………………………. 
4. Name/address/phone numbers, etc. of other contacts/persons/organizations: 
 
5. Product(s) involved: 
6. Batch/lot numbers: 
7. Name of complaint/report (attach any written correspondence) 
 
8. Have samples been returned for examination? (Give details) 
 
9. Are samples available for collection/examination? (Give details) 
 
10. Results of investigations/Tests (attach other sheets as necessary) 
 
11. Conclusions, and decision on action to be taken 
 
Signed ………………… Date……………… 
 
12. Letter(s) sent to ……………………Date ………………. 
13. Also considered necessary to inform:        Done/Date: 
 
14. Was decision taken to FREEZE (beyond own on-site stocks) or Recall? 
IF “YES,” RECALL (or FREEZE) SOP MUST BE IMPLEMENTED IMMEDIATELY 
 
   Signed …………………………… 
   Date …………………………. 
COMPLAINT/DEFECT REPORT 
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is also increasing. The main principle underlying contract production and analysis is very 
simple. The work has to be clearly defined, agreed and controlled to avoid 
misunderstandings. The simplest way to avoid such misunderstandings is to have a written 
contract, setting out the duties of all parties to the contract and the standards that must be 
met.  The standards of performance refer not only to product quality standards but also 
many other non-GMP aspects, e.g. relating to financial matters. It must be clear to everyone 
who is the authorized person, having the responsibility and the final authority to release a 
batch for sale.  The contract should also specify clearly what would happen to materials that 
are rejected.   
4.8.1 The contract giver (the client/company) 
The contract giver is responsible for assessing the competence of proposed contract 
accepters that they will be able to do the work.  It must assess whether the companies that 
offer to do the work really have the capability to do it.  This evaluation must also include an 
assessment as to whether they are able to operate in accordance with the GMP principles. 
Once the conclusion has been reached that the contract accepter has not only the technical 
competence but also the GMP competence and then the contract giver must provide a full 
package of technical information to the contract accepter. This means that all the 
information relevant to personnel, premises and equipment must be provided.  If there are 
hazards associated with cross-contamination of other products these must be highlighted. 
Finally, the product made or tested under the contract must only be released by the 
authorized person in compliance with the marketing authorization.  In some cases the 
authorized person may be a designated staff member of the contract accepter if this 
responsibility is delegated in writing by the contract giver and if such delegation is 
permitted by national regulations. 
4.8.2 The contract accepter (contractor) 
The contract accepter also has responsibilities.  The company must be competent to do the 
work.  It means that it has the necessary facilities, premises and equipment, both in type and 
in quantity, to undertake the work.  It must have a manufacturing authorization to do this 
type of work. This means that its staff has the necessary qualifications, training and 
experience to be able to do the work. The contract accepter may not pass the work or any 
part of it on to a (third) subcontractor party without the approval of the contract giver.  
Finally, once a contract accepter has signed the contract, it must not then undertake new 
work which might adversely affect the quality of the existing products.  An illustration of 
this would be to take on manufacture a penicillin product in the same facility, as other 
products of the contract giver. 
4.9 Self-inspection, quality audits and supplier’s audits/approval 
The purpose of self-inspection is to evaluate the manufacturer’s compliance with GMP in all 
aspects of production and quality control. The self-inspection programme should be 
designed to detect any shortcomings in the implementation of GMP and to recommend the 
necessary corrective actions. Self-inspections should be performed routinely, and may be, in 
addition, performed on special occasions, e.g. in the case of product recalls or repeated 
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rejections, or when an inspection by the health authorities is announced. The team 
responsible for self-inspection should consist of personnel who can evaluate the 
implementation of GMP objectively. Management appoints a self-inspection team consisting 
of experts in their respective fields and familiar with GMP.  
The frequency at which self-inspections are conducted may depend on company 
requirements but should preferably be at least once a year. A report should be made at the 
completion of a self-inspection. The report should include: (a) self-inspection results; (b) 
evaluation and conclusions; and (c) recommended corrective actions. All recommendations 
for corrective action should be implemented. The procedure for self-inspection should be 
documented, and there should be an effective follow-up programme. It may be useful to 
supplement self-inspections with a quality audit. A quality audit consists of an examination 
and assessment of all or part of a quality system with the specific purpose of improving it. A 
quality audit is usually conducted by outside or independent specialists or a team 
designated by the management for this purpose. Such audits may also be extended to 
suppliers and contractors. 
The person responsible for QC should have responsibility together with other relevant 
departments for approving suppliers who can reliably supply starting and packaging 
materials that meet established specifications. Before suppliers are approved and included 
in the approved supplier’s list or specifications, they should be evaluated. The evaluation 
should take into account a supplier’s history and the nature of the materials to be supplied. 
If an audit is required, it should determine the supplier’s ability to conform to GMP 
standards (WHOTRS 961, 2011).  
The practice of supplier audit is difficult to conduct specially when the suppliers are in 
distance form the auditing company and/or the requirement of the auditing company are 
not of significant in values where is supplier is not interested with the party to do the 
business. This difficulty arises with the companies operating in developing countries with 
small business volume. With small business volume, the company’s requirements are such 
that the process of conducting supplier audit shall be a costly affair in one end and the 
supplier shows not interest in the other end. In such cases, an alternative ways need to find 
out for supplier approval. In such case the suppliers are approved based on their history 
and list of customers of the suppliers. Another approach may be to form a group of all small 
companies together so that the quantities required in common are pulled together to create 
interest on the supplier for the business. All the companies in together can have an audit for 
approval of the supplier. In such cases of difficulty in supplier approval, all the initial 
supplies made are subjected for 100% sampling and test before approval of the material 
supplied. 
4.10 Personnel, training and personal hygiene 
The quality of a product ultimately depends on the quality of those producing it…. 
- Sir Dereck Dunlop (1971) 
The establishment and maintenance of a satisfactory system of quality assurance and the 
correct manufacture and control of pharmaceutical products and active ingredients rely 
upon people.  For this reason there must be sufficient qualified personnel to carry out all the 
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tasks for which the manufacturer is responsible. Individual responsibilities should be clearly 
defined and understood by the persons concerned and recorded as written job descriptions 
(WHOTRS 961, 2011). Personnel should be aware of the principles of GMP that affect them 
and receive initial and continuing training, including hygiene instructions, relevant to their 
need (Sharp, 2005). In order to effectively monitor and control virtually all GMP 
documents/activities in a facility, the quality professional should have a very high level of 
knowledge, skills, and experience. Figure 6 represents a comprehensive list of the 
knowledge and skills needed for high level quality professional in the 21st century (Nally, 
2007).   
It is the people (the “men” — the human species, not the gender —or the personnel) that are 
the most important factor in the assurance of quality. This is true of all levels within an 
organization, from company president and managing director to the most-junior employee. 
It may well be possible (if not altogether desirable) for high-quality, well-trained, dedicated 
personnel to compensate for a lack or deficiency in the other elements. Nothing, not even 
the finest premises, equipment, materials, or procedures can compensate for the quality 
hazard represented by low-standard, ill-trained, or poorly motivated staff. Self-responsible, 
well-motivated staff will produce more goods, with a greater assurance of the quality of 
those goods, than will poorly motivated staff. Conversely, in the special context of 
medicines manufacture, poorly motivated staff can represent a hazard to themselves, to the 
public, and to company profits (Sharp, 2005). 
4.10.1 Training system 
Because the quality of the product is directly affected by actions that personnel take in their 
jobs, there must be assurance that they are properly trained. This assurance is built by 
having a training system that is robust, compliant, and sustainable and is able to produce 
individuals who are qualified (Nally, 2007). Elements that are needed in a strong training 
system include the following: an accurate description of the job or role; specific training 
requirements for each job or role; training plan to accomplish the training; training materials 
that are applicable to each type of training; qualified trainers to perform the training; 
evaluations to measure the effectiveness of the training; and a documentation and record 
keeping system for storage and retrieval of training records and materials. 
Job Description: A job description should define the job and role of the individual. It should 
be fairly high level and include major job functions, not tasks the individual performs. The 
function may be divided into duties and responsibilities, competencies that an individual 
may have, and prerequisites needed (e.g., must be a college graduate, must have five years 
of experience, etc.). The manager is expected “to define appropriate qualifications for each 
position to help ensure individuals are assigned appropriate responsibilities.”  
Training Requirement: When a job description has been created and approved by both 
human resources and the functional area, training requirements can then be defined. The 
knowledge and skills the individual needs to successfully perform the job should be 
identified. The desired skills and knowledge are compared against the individual’s skills 
and knowledge when entering the position; gaps are identified. The training requirements 
will be derived from the identified gaps. Training requirements must be updated on a 
periodic basis. Training requirements should be established for all levels within the 
organization. 
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Fig. 6. Knowledge and Skill Requirements for Today’s Quality Professional (Source: Nally, 
2007) 
Business Knowledge/Understanding 
 Policies/Standards/Regulations 
 Manufactured Products 
 Pharm/Bio Industry Knowledge (Rx, OTC) –
local 
 Global 
 General Business (Mfg., Logistics, TS, Eng.) 
 HR, Finance, Marketing/Sales, IS 
Manufacturing 
 Formulation & Manufacturing Procedures 
 Statistical Process Controls 
 Process Capability 
 Equipment & Processing Parameters 
 Environmental Monitoring 
 
Leadership & Management Skills 
 Facilitation and Training 
 Positive Regard and Motivation 
 Performance Assessment/Feedback/Coaching 
 Team Building 
 Networking 
 
Chemistry/Microbiology 
 Good Laboratory Practices 
 Latest Instrumentation & Automation 
 LIMS or Lab Management system 
 Methods Development 
 Methods Validation 
 
Communication Skills 
 Oral 
 Written 
 Presentation 
 Influencing 
 Negotiation and Conflict Management 
 Language 
 
Audit/Assessment (Auditor) Skills 
 Pharmaceutical/Biological Operations 
 Packaging Materials Operations 
 Bulk Pharmaceutical Chemical (BPC) Op. 
 ISO 9000 
 Process/System Approach 
 
Process Skills 
 Time Management 
 Quality Planning 
 Proposal Preparation 
 Project Management & Planning 
 Process Management 
 Change Management 
 Problem Solving/Decision making 
 Management Tools 
 Risk Analysis & Management 
 
Suppliers/Contractors/Third Parties 
 Quality Assurance of Suppliers 
 Quality Assurance of Third Parties 
 Partnership Management 
 
Quality Systems 
 Policies/Procedures 
 Annual Product Review (APR) 
 Complaints 
 Failure Investigations/Materials Decisions 
 Product Release 
 Change Control 
 Components, 
Materials/Warehousing/Dist. 
 Calibration & Maintenance 
 Management Notification 
 Training 
 Recall 
 Technology Transfer 
 
Quality Design & Prevention 
 Basic Quality Tools 
 Process Capability and Statistical QC 
 Process/System Design 
 Design of Experiments (DOE) 
 Failure Mode Effect Analysis (FMEA) 
 Value Engineering/Analysis & Re-Engineering 
 Benchmarking 
 
Validation 
 Facilities/Critical Plant Systems (IQ/OQ/PQ) 
 Production Equipment (IQ/OQ/PQ) 
 Manufacturing Process Validation 
 Retrospective Process Validation (data review) 
 Equipment Cleaning Validation 
 Computer System Validation 
 
Customer Awareness/Understanding 
 Complaint Handling 
 Product Audits/Competitive Comparisons 
 Customer Visits/Interviews 
 Market/Customer Surveys 
 Next Operation as Customer (NOAC) 
 Six Sigma Approach 
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Training Plan: To ensure that the individual receives the “right” training at the “right” time, 
an individual training plan should be created and executed for each individual. The 
individual’s curriculum should include procedural (knowledge) training, usually SOPs, and 
competency-based skills training (on-the-job training or OJT). Both these types of training 
should be standardized as much as possible with the same training material used for all 
trainees. The individual’s curriculum will include different levels of training. These can be 
divided into three levels. The first level is an overview or general training conducted by the 
site HR or corporate training group as part of a new hire or induction training. The second 
level is held within the functional area. The third level, most specific to the employee, is one-
on-one training (Figure 7). The training plan should include an approximate training time. 
The site may have an annual or semi-annual training plan that defines what GMP training 
should be given to functional areas at the site and when. 
 
Fig. 7. Training System (Source: Nally, 2007) 
Training Materials: Training materials should be designed and developed for most training. 
Whether the training is given once or many times, the information should be the same. The 
training material should be clear and well organized. Training materials should contain 
stated objectives. In addition to the content being trained, the reason behind the training 
should be explained and stressed. If training GMPs, the impact of the particular training on 
the production of the product should be explained.  
Qualified Trainers: GMP training to be given by qualified personnel, the company should 
have a procedure and process for qualifying trainers. Minimum requirements for trainers 
 
Level 1 
 
Level 2 
 
Level 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Job 
Description 
 
Evaluation 
Individual 
Training 
Plan 
Training 
Requirements 
Appropriate 
Training 
Event 
 
Documentation 
 
Qualified 
Trainers 
Approved and 
Accurate Training 
Material 
Knowledgeable 
Training 
Designers 
Broad general knowledge, 
Introduction to GMP 
Application of specific 
GMPs to the Functional 
Application 
of GMPs to a 
Specific Job 
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may include some formal education (e.g., Train-the-Trainer course) or experience in 
presenting training, subject matter expertise in the subject they will be training, 
understanding of GMPs in terms of how it impacts the specific training they are responsible 
for, and the knowledge about how to train adults. Trainers should be selected for their 
ability to help individuals learn. If they are on-the-job trainer, they should be able to 
demonstrate the skills and also clearly explain how to perform the skill.  
Evaluation, Documentation/Record Keeping: Job skills and GMP training should be 
evaluated. For GMP training, evaluation tools such as questionnaires, case studies, 
discussions, and other tools may be used. For job skills, a performance-based evaluation is 
used. The usual method is to have an observer watch the individual in training and 
complete a checklist. The individual should be able to demonstrate the correct practice 
without the coaching or help from another individual. The performance checklist is usually 
signed by the trainee and by a member of management. This document is retained. 
Evaluations should be performed after the training. The training system and training 
processes should be documented, possibly in an SOP, describing how the training system 
works and the type of training included in the training system. Training records should be 
retained in a documentation system. There should also be a method to ensure that training 
curricula and training requirements are up-to-date in the event that an individual transfers 
to another job within the company. Any changes made to curricula should be documented 
and approved. Training documentation should be readily retrievable (Nally, 2007). 
There should be two types of training records: 
1. The personal file of each member of staff should contain a record of the training 
received, indicated by module reference number (see Figure 8).  
2. Departmental training records should be maintained, indicating in tabular form the 
training received by each member of staff (see Figure 9). 
 
Fig. 8. Personal Training Record (Source: Sharp, 2005) 
 
Name GI/1 GI/2 GMP/1 GMP/2 GMP/3 GMP/4 GMP/5 STT/1 STT/2 
          
          
          
Fig. 9. Company Training Record (Source: Sharp, 2005) 
ABC Company 
Personal Training Record 
Name: …………………………………… Date Joined Company…………………. 
Job Title: 
1. ……………………………………….. 
2. ……………………………………….. 
3. ……………………………………….. 
Training Record (module ref. and title)   Date 
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The concept of personal hygiene is described in the subheading of Sanitation and hygiene. 
4.11 Premises 
Premises must be located, designed, constructed, adapted, and maintained to suit the 
operations to be carried out. The layout and design of premises must aim to minimize the 
risk of errors and permit effective cleaning and maintenance in order to avoid cross-
contamination, build-up of dust or dirt, and, in general, any adverse effect on the quality of 
products. Although the most important single factor in the assurance of the quality of 
medicinal products is the quality of the people who manufacture them, the premises in 
which they are manufactured will also have an important bearing on the quality of those 
products (Sharp, 2005). Pertinent consideration should be made prior to the selection of 
location for construction of pharmaceutical premises or alteration of existing facilities to 
ensure that the surrounding neighborhood is free form unsanitary environmental condition.  
The choices of materials of construction for manufacturing facilities are numerous. Some 
examples are presented subsequently.  
a. Walls. Walls in manufacturing areas, corridors, and packaging areas should be of plaster 
finish on high-quality concrete blocks or gypsum board. The finish should be smooth, 
usually with enamel or epoxy paint.  They should be washable and able to resist repeated 
applications of cleaning and disinfecting agents. Internally, there should be no recesses that 
cannot be cleaned, and a minimum of projecting ledges, shelves, fixtures and fittings. 
b. Floors. Floor covering should be selected for durability as well as for cleanability and 
resistance to the chemicals with which it is likely to come into contact. Terrazzo provides a 
hard-wearing finish; both tiles and poured-in-place finishes are available. The latter is 
preferable for manufacturing areas; if tiles are used, care must be taken to ensure effective 
sealing between the tiles, which, otherwise, could become a harboring area of dirt and 
microorganisms. Welded vinyl sheeting provides an even, easy to clean surface. Epoxy 
flooring provides a durable and readily cleanable surface. However, the subsurface finish is 
extremely important. Where drains or drainage gullies are installed, they should be easily 
cleanable and trapped to prevent reflux.  
c. Ceilings. Suspended ceilings may be provided in office areas, laboratories, toilets, and 
cafeterias. They usually consist of lay-in acoustical panels of non brittle, non friable, non 
asbestos and non combustible material. Manufacturing areas require a smooth finish, often 
of seamless plaster or gypsum board. All ceiling fixtures such as light fittings, air outlets and 
returns should be designed to assure ease of cleaning and to minimize the potential for 
accumulation of dust. 
d. Services. In the building design, provisions must be made for drains, water, steam, 
electricity, and other services to allow for ease of maintenance. Access should, ideally, be 
possible without disruption of activity within the actual rooms provided with the services.  
Doors and window-frames should all have a smooth, hard, impervious finish, and should 
close tightly. Window and door frames should be fitted flush, at least on sides facing inward 
to processing areas. Doors, except emergency exits, should not open directly from 
production areas to the outside world. Any emergency exit doors should be kept shut and 
sealed, and designed so as to be openable only when emergency demands. Despite the 
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space-saving advantages, sliding doors should be avoided because of the difficulty of 
maintaining the sliding gear in a clean condition. 
The layout design of the facility must minimize the possibility of mix-ups or contamination. 
Sufficient space must be provided to allow adequate separation of adjacent equipment and 
operations. An example of this includes the spatial separation of packaging lines so that 
packaging components, bulk product, and finished product cannot intermix between lines 
and that dust or spillage from one line cannot result in the contamination of adjacent 
equipment. For example, a common practice is to introduce a physical barrier between the 
packaging lines. The layout of the manufacturing and support operations must account for 
efficient material, personnel, and equipment flow patterns. Adequate access control is 
required to restrict entrance to manufacturing areas. The most efficient and compliant flow 
pattern is the one that provides for unidirectional flow.  
Temperature and humidity need to be controlled primarily for the comfort of operators. The 
gowning requirements to minimize the potential for microbial contamination from 
operators are rather stringent and can easily cause personal discomfort, which could, in 
turn, adversely impact on the aseptic processing. Conditions in the order of 68°F /20°C 
(65°F/18°C -70°F/21°C) and 45% (40%-50%) relative humidity have been found to be 
suitable. Independent of gowning requirements, relative humidity ranges must be carefully 
selected. Continuous relative humidity levels below 15% can cause static electricity 
discharge and health concerns and levels above 60% can be the source of microbial growth 
and corrosion (Signore & Jacobs, 2005).  
4.11.1 Layout concepts 
A very basic block design showing a simple single-storey linear flow layout is given in 
Figure 10. The internal building requirements vary according to the nature of the operations 
carried out or type of product produced within the various departments, sections, or rooms 
(Sharp, 2000). Within the facility there will be various flow-patterns. These flows will be 
principally of materials and products, and of personnel. Materials will be received, held 
pending test, released for use, held in store, dispensed for manufacture, and processed into 
products that are then packaged, tested, and held in quarantine pending release, and then 
stored pending distribution.  
 
Fig. 10. Simple Single-Story Linear Flow Pattern for Pharmaceutical Manufacturing. 
Sampling Quarantine and Release Stages not shown. Not a scale (Source: Sharp, 2000) 
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Fig. 11. Single-Story Linear Flow Pattern for a Tablet Manufacturing Unit (Detail Design) 
QC Area is not shown. Not a Scale 
A horizontal layout plan for manufacturing tablet dosage form with detail drawing is 
shown in Figure 11. The layout is considered as the smallest possible design of 7150 sq. ft. 
area covering all requirements of manufacturing and packaging including stores area for a 
tablet manufacturing unit.  The design does not cover QC and other supporting areas such 
as canteen, engineering and/or administration rooms. 
Most of the required pipe works are taken from inside the wall in concealed manner. 
Exposed pipelines should not touch walls but be suspended from or be supported by 
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brackets, sufficiently separated to allow through cleaning. The pipe works at exposed 
surfaces are required to be clearly marked with direction flow of the utilities used. In 
general all the exposed pipelined inside the processing area is made of SS 304 grade with 
exception of SS 316L for those used in supply of purified water. Different colour codes are 
used for identification of the utility pipe lines (Table 3).  
 
Utility used Pipe colour code Colour of letter for legend 
Pressurized steam Red Black 
Compressed air Orange Black 
Vacuum Yellow Black 
Nitrogen Grey Black 
Oxygen Light Blue Black 
LPG Dark Green Black 
Carbon dioxide Violet Black 
Distilled water (water for injection) White Black 
Deionized water Light Green Black 
Well water/ water for fire fighting Black White 
Table 3. Identification of Pipelines (Source: ASEAN, 2000) 
A manufacturing facility, built and finished as designed, still requires various other inputs, 
in addition to people, equipment, and materials, before the manufacture of products can 
begin. These can be referred to collectively as “plant services, systems, and utilities.” 
Heating, ventilation, and air-conditioning (HVAC), Lighting, Water for pharmaceutical use 
(WPU), Electricity and Gases/Compressed air are considered as the major plant services, 
systems and utilities requirements for a pharmaceutical unit. 
4.11.2 Heating, Ventilation and Air-Conditioning (HVAC) 
“Natural” ventilation (via doors and windows) is not acceptable in medicine manufacturing 
area because of the risk of product contamination from the outside world (particulate 
matter, dust, dirt, microorganisms, insects, etc.). Control of humidity is also important for a 
number of products, particularly effervescent products. Windows from production areas to 
the outside world should thus normally remain closed, and preferably not be openable. 
External doors should be air locked, or only openable in an emergency. Therefore, some 
form of forced; conditioned, usually filtered, air supply is required with proper heating, 
ventilation and air-conditioning (HVAC) system (WHOTRS 937, 2006).  
HVAC play an important role in ensuring the manufacture of quality medicinal products. A 
well designed HVAC system will also provide comfortable conditions for operators. HVAC 
system design influences architectural layouts with regard to items such as airlock positions, 
doorways and lobbies. The architectural components have an effect on room pressure 
differential cascades and cross-contamination control. The prevention of contamination and 
cross-contamination is an essential design consideration of the HVAC system. In view of 
these critical aspects, the design of the HVAC system should be considered at the concept 
design stage of a pharmaceutical manufacturing plant.  
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Fig. 12. Examples of Pressure Cascade (Source: WHOTRS 937, 2006) 
While designing the HVAC system following parameters are required to be considered for 
operation of oral solid dosage (OSD) formulations avoiding cross contamination. The 
operating room should be of Class 100000 condition. The dispensing room used for 
weighing raw materials and sampling room used for raw material sampling for testing 
should be provided with reverse laminar air flow system with Class 100 condition. The most 
widely accepted pressure differential for achieving containment between two adjacent zones 
is 15 Pa, but pressure differentials of between 5 Pa and 20 Pa may be acceptable (WHO TRS 
937, 2006). The door in the room should always open towards the high pressure area (Figure 
12). The air changes per hour in the operating room that is the times the volume of air 
supplied per hour in comparison to the volume of room should be at least 20 per hour. In 
general room temperature and humidity maintained at 22±3°C and 50±5% respectably have 
been found to be suitable for personal comfort.                                    
The HVAC system may be designed either with 100% fresh air system or with 85-90% 
reticulated air system. In case of recirculation system the supply air stream is to be provided 
with high-efficiency particulate air (HEPA) filters to remove contaminants, and thus prevent 
cross-contamination. Recirculated air should not be used if there are no HEPA filters 
installed in the system, unless the air handling system is serving a single product facility. In 
case of 100% fresh air system the degree of filtration on the supply air and exhaust air 
should be determined depend on the level of cleanliness required; exhaust air contaminants 
and local environmental regulations. The required degree of air cleanliness in most OSD 
manufacturing facilities can normally be achieved without use of HEPA filters.  In locations 
with different climatic conditions, difference between a systems operating on 100% fresh air 
versus a system utilizing recirculated air with HEPA filtration should be considered in the 
context of cost of installation as against operating cost.  
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4.11.3 Lighting 
Lighting levels should be adequate to permit operators to do their work properly, 
accurately, and attentively. Lighting of production and packaging areas should be 
sufficiently bright to enable good vision (Table 4). Although daylight is preferable from a 
number of aspects, it needs to be noted that a number of pharmaceutical products and 
materials are affected by UV light. The design and layout of a modern pharmaceutical 
factory also usually make artificial lighting inevitable. It should be installed so as not to 
create uncleanable dust traps, e.g., preferably flush-fitted to the ceiling, or with smooth 
easily accessible and cleanable surfaces. To avoid photo degradation, a suitable light using 
sodium vapor lamp is to be provided with dispensing/sampling booth for 
weighing/sampling of highly light sensitive materials. 
 
Illumination intensity 
(in Lux) 
Specific Area 
20 - narrow corridor, aisle 
50 - warehouse for big size containers, corridor for personal traffic 
100 
- corridor for traffic of personnel and forklift, break room, locker 
rooms, rest rooms, utility rooms, staircase lobby 
200 - workshop, warehouse 
300 - laboratory 
500 - offices with reading activities, production room, first aid room 
750 - draft room 
1000 - visual inspection 
1 foot candle = 1 lumen/ feet2 = 10.764 lux 
(ft.c)                     lm/ ft2 
Table 4. The Recommended Illumination in Premises (Source: ASEAN, 2000) 
4.11.4 Water for Pharmaceutical Use (WPU) 
Water is the most widely used substance in the production, processing and formulation of 
pharmaceutical products. It has unique chemical properties due to its polarity and hydrogen 
bonds. This means it is able to dissolve, absorb, adsorb or suspend many different 
compounds. These include contaminants that may represent hazards in themselves or that 
may be able to react with intended product substances, resulting in hazards to health 
(WHOTRS 929, 2005). 
Different grades of water quality are required depending on the route of administration of 
the pharmaceutical products. Control of the quality of water throughout the production, 
storage and distribution processes, including microbiological and chemical quality, is a 
major concern. Unlike other product and process ingredients, water is usually drawn from a 
system on demand, and is not subject to testing and batch or lot release before use. 
Assurance of quality to meet the on-demand expectation is, therefore, essential. 
Additionally, certain microbiological tests may require periods of incubation and, therefore, 
the results are likely to lag behind the water use. Control of the microbiological quality of 
WPU is a high priority. Some types of microorganism may proliferate in water treatment 
components and in the storage and distribution systems. It is very important to minimize 
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microbial contamination by routine sanitization and taking appropriate measures to prevent 
microbial proliferation (WHOTRS 929, 2005). 
Pharmaceutical water production, storage and distribution systems should be designed, 
installed, commissioned, validated and maintained to ensure the reliable production of 
water of an appropriate quality. Where chemical sanitization of the water systems is part of 
the biocontamination control programme, a validated procedure should be followed to 
ensure that the sanitizing agent has been effectively removed. Steam sanitization is 
considered as one of the best alternative for WPU system. Water may be originally obtained 
from a number of sources. Water from wells or bore-holes, given suitable treatment, has 
been used to manufacture pharmaceuticals. In many countries, the most usual source is 
normal mains, or town, water of potable (drinkable) quality. For pharmaceutical purposes, it 
may be considered that there are four basic grades of water: 
Drinking Water is unmodified except for limited treatment of the water derived from a 
natural or stored source. Examples of natural sources include springs, wells, rivers, lakes 
and the sea. The condition of the source water will dictate the treatment required to render it 
safe for human consumption (drinking). It is common for drinking-water to be derived from 
a public water supply that may be a combination of more than one of the natural sources 
listed above. Typical processes employed at a user plant or by a water supply authority 
include: filtration, softening, disinfection or sanitization (e.g. by sodium hypochlorite 
(chlorine) injection), iron (ferrous) removal, precipitation, and reduction of specific 
inorganic/organic materials. 
Purified Water (PW) should be prepared from a potable water source as a minimum-quality 
feed-water, should meet the pharmacopoeial specifications for chemical and microbiological 
purity, and should be protected from recontamination and microbial proliferation. There are 
no prescribed methods for the production of PW in the pharmacopoeias. Any appropriate 
qualified purification technique or sequence of techniques may be used to prepare PW. 
Typically ion exchange, ultra filtration and/or reverse osmosis processes are used. 
Electodionization or Distillation can also be used. Ambient-temperature PW systems are 
especially susceptible to microbiological contamination, particularly when equipment is 
static during periods of no or low demand for water. It is essential to consider the following 
mechanisms for the efficient control of contamination. 
 The headspace in the storage vessel is an area of risk where water droplets and air can 
come into contact at temperatures that encourage the proliferation of microbiological 
organisms. The water distribution loop should be configured to ensure that the 
headspace of the storage vessel is effectively wetted by a flow of water. The use of spray 
ball or distributor devices to wet the surfaces should be considered. 
 Nozzles within the storage vessels should be configured to avoid dead zones where 
microbiological contamination might be harboured. 
 Vent filters are fitted to storage vessels to allow the internal level of liquid to fluctuate. 
The filters should be bacteria-retentive, hydrophobic and ideally be configured to allow 
in situ testing of integrity. Offline testing is also acceptable.  
 Where pressure-relief valves and bursting discs are provided on storage vessels to 
protect them from over-pressurization, these devices should be of a sanitary design.  
 Maintenance of continuous turbulent flow circulation within water distribution systems 
reduces the propensity for the formation of biofilms.  
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 For ambient temperature systems, pipework should be isolated from adjacent hot pipes. 
Deadlegs in the pipework installation greater than 1.5 times the branch diameter should 
be avoided. 
 Pressure gauges should be separated from the system by membranes. 
 Hygienic pattern diaphragm valves should be used. 
 Pipework should be laid to falls to allow drainage. 
 The growth of microorganisms can be inhibited by: ultraviolet radiation sources in pipe 
work; maintaining the system heated (guidance temperature 70–80 °C); sanitizing the 
system periodically using hot water (guidance temperature >70 °C); sterilizing or 
sanitizing the system periodically using superheated hot water or clean steam; and  
routine chemical sanitization using ozone or other suitable chemical agents. When 
chemical sanitization is used, it is essential to prove that the agent has been removed 
prior to using the water. Ozone can be effectively removed by using ultraviolet 
radiation. 
4.11.5 Electricity 
In general the electricity supply is made through concealed wiring with five wires (three 
phase wires, one neutral wire and  one ground wire) for three-phase connections and three 
wires (one phase wire, one neutral wire and one ground wire) for single-phase connections 
using suitable size wires. Conductors of a three-phase system are usually identified by a 
color code, to allow for balanced loading and to assure the correct phase rotation for 
induction motors. Colors used may adhere to International Standard IEC 60446, older 
standards or to no standard at all and may vary even within a single installation. For 
example, in the U.S. and Canada, different color codes are used for grounded (earthed) and 
ungrounded systems (Wikipedia. (2012b). In case of India, Pakistan and Nepal, generally 
red, yellow and blue color wires are used for three phases L1, L2 and L3 connections, black 
for neutral and green for ground connections.   
Continuity of electricity supply is essential for a number of systems or processes (air supply 
and extraction, particularly for sterile manufacture; fermentation plants; incubators; stability 
chambers) and thus backup systems should be available in the event of mains failure. 
Ideally, there should be automatic changeover and reset from mains to emergency generator 
supply. Certain equipment (computers, microprocessor control systems, some analytical 
instruments) may need voltage stabilization in order to operate reliably (Sharp, 2005). 
4.11.6 Gases/compressed air 
Various gases may be used for a variety of purposes, for example, inert gases used as a 
protective “blanket” or to displace air in an ampoule head-space, as propellants in aerosol 
products, as sterilants (e.g., ethylene oxide), as a source of flame in glass ampoule sealing. 
Any gas that may come into contact with a product (or product contact surfaces), or that is 
used in the manufacture of a product, must be treated as if it were a raw material and must 
therefore be subject to standard quality control procedures to ensure that it conforms to 
predetermined quality standards. A number of gases are used in laboratory test procedures. 
If these are not of the required or specified quality, then the reliability of the test results may 
suffer. Gas pipelines, from cylinders or from bulk gas storage, should be clearly marked as 
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to contents. It should not be possible to switch pipelines and connections and thus to supply 
the wrong gas. Dedicated, pin-indexed valves and connections, as (one hopes) used in 
hospital gas supply lines, should be employed where possible. 
Gases (including compressed air) may need to be filtered when supplied to production areas 
generally. Gases (including compressed air), when supplied to sterile products 
manufacturing areas (and other controlled environments), will certainly need to be filtered 
(as close to the point of use as possible) to ensure that they conform to the particulate and 
microbial standards for the area (Sharp, 2005). In general the compressed air coming in 
contact with OSD products is recommend to be oil and moisture free with particulate matter 
filtered through initial coarse and terminal 1µ filters.   
4.12 Equipment 
Manufacturing equipment should be capable of producing products, materials, and 
intermediates that are intended and that conform to the required or specified quality 
characteristics.  Furthermore, the equipment must be designed and built so that it is possible 
(and relatively easily possible) to clean it thoroughly. Surfaces that come into contact with 
products should have smooth, polished finishes, with no recesses, crevices, difficult corners, 
uneven joints, dead-legs, projections, or rough welds to harbor contamination or make 
cleaning difficult. Equipment must also be capable of withstanding repeated, thorough 
cleaning. Traces of previous product, at levels that might be acceptable in other industries, 
are totally unacceptable in the manufacture of medicines.  
As far as the properties of the materials of construction of the equipment are concerned, 
there are two major concerns: 
1. The possibility of contamination, or degradation, of the product by the material from 
which the equipment is constructed 
2. The action of the product, or material in-process, on the material from which the 
equipment is constructed 
Contamination of product can arise from shedding or leaching of contaminants from the 
equipment into the product or from reaction between the product and the material of the 
equipment. It is worth remembering that there are two aspects of the potential release of 
product contaminants by equipment: they could be toxic to patients, even in very small 
amounts, and they could cause product decomposition. As an example of the latter — 
penicillin can be inactivated by trace heavy metals. 
Fixed equipment should be installed, piped in, and supplied with services in a manner that 
creates a minimum of recesses, corners, or areas that are difficult for cleaning. The 
equipment should be designed and located to suit the processes and products for which it is 
to be used. It must be shown to be capable of carrying out the processes for which it is used 
(that is, it should be properly commissioned, or “qualified”) and of being operated to the 
necessary hygienic standards. It should be maintained so as to be fit to perform its functions, 
and it should be easily and conveniently cleanable, both inside and out. Parts that come into 
contact with materials being processed should be non reactive or absorptive with respect to 
those materials. Equipment should be kept and stored in a clean condition and checked for 
cleanliness before each use. 
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Between batches (or “campaigns”) all manufacturing equipment must be thoroughly 
cleaned and (as necessary) disinfected or sterilized. There should be written procedures for 
doing this, which must be followed exactly. The cleaning program consists of two parts—
the validation of the processes and detergents/sanitization agents and the day-to-day use of 
the validated processes and qualified detergents and sanitizers. Many cleaning processes are 
automated. These falls into two classes: clean in place (CIP) and clean out of place (COP). 
The CIP systems have their equipment provided with hard-piped services with cleaning 
solutions. The cleaning process is automated and usually is documented through a printout 
of the automation system. The COP systems consist of bringing the equipment to a cleaning 
station or placing the equipment in an automated washer.  
Effectiveness of cleaning is a function of a number of factors, including time, temperature, 
and rate of turbulent flow of the cleaning solution; the concentration of chemical cleaning 
agents in the cleaning solution; and the surface finish (smoothness or roughness) of the 
surfaces to be cleaned. All these factors interact. For example, all other things being equal, it 
will take a longer time to completely clean a relatively rough internal surface as compared to 
a high-polish, smooth one. Higher temperatures will need lower times and flow rates, and 
so on. Cleaning solutions commonly employed contain caustic agents and detergents, and it 
must be remembered that, before cleaning is complete, it is necessary to ensure removal of 
the cleaning agents themselves. That is, there must be a rinsing stage, using (for aqueous 
products) water of a quality appropriate to, and compatible with, the products to be 
manufactured in the equipment. 
4.13 Materials 
A flow diagram illustrating the ordering, receipt, sampling, approval (or rejection), and 
dispensing of starting materials is shown in Figure 13. The purchasing department orders 
the material on the basis of a starting material specification provided to them by the QC. 
Purchasing department sends the order to an approved supplier, which is a company that 
has been approved, jointly by the QA, QC and production to supply the material in 
question. To continue with the flow-diagram, at the time of placing the order, the 
purchasing department sends a copy of the purchase order to the goods inwards (or 
receiving) department, where it is (accessibly) retained, pending the receipt of the goods. 
On receipt, the goods are carefully examined by a responsible member of the goods inwards 
department for general condition, and to check for any signs of external damage, soiling, or 
dampness. At the same time, the labeled identity of the delivered material is checked and 
compared with the goods inwards copy of the purchase order, and with any supplier’s 
delivery, or advice note, to confirm that the material delivered is, as far as its labeling is 
concerned, the material that was ordered. A check is also made at this time on all the 
identity labels on the containers in a multi container delivery. Different suppliers’ batches 
within one delivery are to be segregated, one from another, with a different internal lot 
number for each entered on the QUARANTINE label, which is applied to each container. If 
all the containers in the delivery appear to be correct and in good condition, the goods 
inwards department then place on each container a QUARANTINE label (see Figure 14), 
with the entries for “Code Number,” “Name of Material,” “Lot Number,” and “Date 
Received” are completed.  
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Fig. 13. Components/Starting Materials Flow Chart (Source: Sharp, 2005) 
Notes: 
a. It is useful to have the QUARANTINE label, and the RELEASED and REJECTED labels 
printed in different colors, for example, for QUARANTINE, black print on a yellow 
background, for RELEASED green print on a white background, and for REJECTED red 
print on a white background. 
b. In the examples shown, the intention is that, when the QC decision is made, the 
RELEASED (or REJECTED) label should be applied just over the lower QUARANTINE 
panel. This may seem an infringement of the golden rule about not applying new labels 
over old ones, but here (if the, say, RELEASED label falls off, or is removed) the labeled 
status of the material reverts to QUARANTINE, i.e., it is fail-safe. The benefit of the 
labeling system illustrated is the elimination of any possible error in transcribing the 
information originally entered on the QUARANTINE label. 
c. It is important that at least the QUARANTINE label is in a house style, with company 
name or logo, to avoid confusion with any other identity and status labels (e.g., those 
applied by vendors) that may already be on the container.  
Goods inwards then completes a materials receiving report (Figure 15) in four copies, 
retaining one copy and sending the other three to QC. They then make the appropriate  
QC Spec. 
Purchase Order 
Approved supplier 
Production 
Quarantine 
Dispense 
QC Sample 
QC Test 
Reject Store 
Manufacture 
or 
Check delivery: 
- Labeled identity (cf. PO) 
- Condition 
- Quantity 
Record: 
- Supplier’s name/code 
- Order no. 
- Supplier’s batch ref. no. 
- Quantity 
- No. of containers 
- In-house batch no. 
“Usable Stock” 
Goods Inwards 
Purchasing Dept. 
QC 
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Fig. 14. Quarantine, Releases and Rejected Labels (Source: Sharp, 2005) 
entries (except for entries in the last two columns) in a departmental running record — a 
“Materials Delivery Record” (Figure 16). This can be a printed sheet or card, or manually 
drawn up in a record book (or a computer record). 
Receipt of the copies of the materials receiving report alerts the QC that the material has 
been delivered, and is required to be sampled. Following sampling (“date sampled__” and 
“by__” on the QUARANTINE label completed by the sampler) and testing against the 
agreed specification, the QC decision is entered on the copies of materials receiving report, 
one copy being sent to the purchasing department (for information), one to materials 
inventory control (so, if material is released, it may be allocated to manufacturing batches), 
and one retained on QC file, with the full analytical report. An authorized member of the 
QC then places a RELEASED (or REJECTED as appropriate) label, over the QUARANTINE 
portion, with the necessary details entered. S/he also enters a date at “retest date__” on the 
original label, to indicate when the material is due for reexamination.  
On receipt of the QC decision, goods inwards either moves the released goods into the 
usable stock area of the stores, or the rejected material to a secure reject store. The two last 
columns of the material delivery record are then completed (“date approved by QC” and 
“location”). 
ABC Inc. 
 
Code No. …………  Material ..…..………….    Lot …..… 
 
Date Rec’d ………….. Date Sampled………… By……… 
 
Retest Date …………………………. 
 
Q U A R A N T I N E 
Code No. …………  Material ..…..……………    Lot …..… 
 
R E L E A S E D 
 
Date …………..   QC Sig. ……………….…. 
 
Code No. …………  Material ..…..………….    Lot …..… 
 
R E J E C T E D 
 
Date …………..   QC Sig. ……………….…. 
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Fig. 15. Goods Inwards -Materials Receiving Report (Source: Sharp, 2000) 
 
Date of 
Delivery 
Material 
Code 
No. 
Lot 
No. 
Quantity 
No. of 
Containers 
Supplier 
No. 
Delivery 
Note 
Supplier’s 
Batch No. 
(s) 
Supplier’s 
Name for 
Materials 
Date 
Approved 
by QC 
Location 
            
            
Fig. 16. Materials Delivery Report (Source: Sharp, 2005) 
4.13.1 Packaging materials 
The purchase, receipt, sampling, release, and control of printed packaging materials and 
primary packaging materials (that is packaging materials that come into direct contact with 
the product, as compared with secondary packaging materials, which do not) need to be 
accorded the same level of attention as given to starting materials. Documents, records, and 
procedures analogous to those outlined above should be employed. All the regulatory 
requirements are in agreement that components or (starting materials) and containers, etc. 
should be stored and handled in a manner that will prevent contamination. Some 
GOODS INWARDS – MATERIALS RECEIVING REPORT 
 
Material………………………………………  Code No. ………… 
 
INSTRUCTIONS:  
1. Complete a separate Receiving Report for each delivery, and for each supplier’s batch   
    number within a delivery 
2. Retain one copy in Goods Inwards file, and send three copies to Quality Control. 
3. Quality Control: On completion of testing, mark this report, where indicated. 
“RELEASED,” “REJECTED,” ”HOLD” as appropriate, and send a copy to: 
 Purchasing Department 
 Materials Inventory Control 
 Retain one copy on Quality Control files 
 
Date goods received  ………………….. 
Supplier  ………………………………………. 
Supplier’s batch no.   ………………….. 
Quantity received  ………………….. 
Number of containers ………………….. 
Purchase order no.  ………………….. 
Assigned lot no.  ………………….. 
 
General condition/cleanliness of delivery 
  …………………………………………… 
  
Delivery examined by (signed) ……………………. Date ……….. 
Remarks/Comments 
 
QUALITY CONTROL DECISION 
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specifically require storage off the floor and suitable spacing “to permit cleaning and 
inspection.” Some guide adds that one of the objectives of storage “in an orderly fashion” is 
to “permit batch segregation and stock rotation” [FEFO, “first expiry, first out” or FIFO 
“first in, first out”]. Storage off the floor guards against damage from flooding and liquid 
spillages. It also permits wet-cleaning of floors, without the risk of wetting the materials. A 
well-laid-out, orderly store not only permits segregation of different types, lots, and batches 
of material (hence, aiding against contamination and mix up) and rotation of stock, it also 
enables more (labor-, management-, and cost-) efficient running of the store. 
4.13.2 Sampling of materials for testing 
It is also important that the containers in which the materials are received should be cleaned 
before the goods are placed in quarantine. A record should be made of all goods received 
(Materials Delivery Record). The GMP requirements agree that received materials (both 
components or starting materials and packaging materials) should be held in a quarantined 
state until they have been sampled, tested for compliance with specification, and formally 
released for use (or rejected and removed from stock). Quarantine status can be established 
and maintained by status labeling, by secure physical segregation (for example in separate 
quarantine store, apart form the usable materials store) or by manual or electronic stock 
control systems. A combination of all three provides the greatest security against 
inadvertent use of material that has not been approved for use.  
The process of sampling can itself pose risks of contamination. For this reason, containers 
may need to be cleaned prior to sampling—a vacuum system is very effective for a large 
container. Small containers may be wiped down with an appropriate solvent or distilled 
water. Containers should be opened for sampling in an acceptable environment that will not 
expose the material to further risk of contamination. This sampling area may be a 
designated room near or adjacent to the warehouse with the provision of reverse laminar 
flow sampling booth  maintaining class 100 condition to avoid cross contamination to or by 
the material being sampled.  
The release of components, containers, and closures for use cannot be for an indefinite time. 
During storage, degradation may occur, moisture may be absorbed, or materials may simply 
become contaminated during the storage process. Re-evaluation time scales should be 
developed from historical data, where possible. Except for particularly sensitive materials, a 
onetime period, often one year, has been established by many manufacturers. Either the 
product release label or the system should clearly indicate when materials are to be re-
evaluated. This re-evaluation will not usually require full testing, but only examination of 
those parameters known to be subject to change. For infrequently used materials, re-
evaluation coincides with just prior to the use of the material. 
4.14 Documentation 
Good documentation is an essential part of the QA system and, as such, should exist for all 
aspects of GMP. Its aims are to define the specifications and procedures for all materials and 
methods of manufacture and control; to ensure that all personnel concerned with 
manufacture know what to do and when to do it; to ensure that authorized persons have all 
the information necessary to decide whether or not to release a batch of a medicine for sale, 
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to ensure the existence of documented evidence, traceability, and to provide records and an 
audit trail that will permit investigation. It ensures the availability of the data needed for 
validation, review and statistical analysis. The design and use of documents depend upon 
the manufacturer (WHO TRS 961, 2011).  
The various types of documents used should be fully defined in the manufacturer's quality 
management system (QMS). Documentation may exist in a variety of forms, including 
paper-based, electronic or photographic media. The main objective of the system of 
documentation utilized must be to establish, control, monitor and record all activities which 
directly or indirectly impact on all aspects of the quality of medicinal products. The QMS 
should include sufficient instructional detail to facilitate a common understanding of the 
requirements, in addition to providing for sufficient recording of the various processes and 
evaluation of any observations, so that ongoing application of the requirements may be 
demonstrated (EudraLex, 2012). 
There are two primary types of documentation used to manage and record GMP 
compliance: instructions (directions, requirements) and records/reports. Appropriate good 
documentation practice should be applied with respect to the type of document. Suitable 
controls should be implemented to ensure the accuracy, integrity, availability and legibility 
of documents. Instruction documents should be free from errors and available in writing 
(EudraLex, 2012). 
‘If it’s not written down, then it didn’t happen!’ The basic rules in any GMP regulations 
specify that the pharmaceutical manufacturer must maintain proper documentation and 
records. Documentation helps to build up a detailed picture of what a manufacturing 
function has done in the past and what it is doing now and, thus, it provides a basis for 
planning what it is going to do in the future. Regulatory inspectors, during their inspections 
of manufacturing sites, often spend much time examining a company’s documents and 
records. Effective documentation enhances the visibility of the quality assurance system. 
Issue and use of documents should be under formal control. They should be available to all 
who need them, and not available to those who do not. They should be kept up-to-date, but 
all revisions should be formal and authorized, not haphazard. The documentation system, 
overall, should be subject to review. It is vital that systems exist for the removal from active 
use of outdated or superseded documents. (Sharp, 2005) 
In the manufacture of anything as important to human health and well-being as medicinal 
products, every activity must be preplanned and formally defined in advance. Nothing can 
be left to chance. There is no room for “playing it by ear” or “by the seat of the pants.” 
Manufacture of consistent quality drug products demands consistent, predetermined, 
defined activity. 
The objectives are, in short:  
1. To state clearly, in advance and in writing, what is to be done 
2. To do it — in accordance with those instructions 
3. To record what was done and the results of doing it 
The reasons for all this documentation are: 
1. To ensure there is no doubt about what has to be done, by having formally approved 
written instructions for each job, and then following them 
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2. To define standards for materials, equipment, premises, services, and products 
3. To confirm, as work proceeds, that each step has been carried out, and carried out 
correctly, using the correct materials and equipment 
4. In the longer term, to keep, for later reference, records of what has been done, for 
example, manufacturing and test records, installation, commissioning, servicing, and 
maintenance records 
5. To enable investigation of complaints, defect reports, and any other problems, and to 
permit observation of any drifts away from defined quality standards 
6. To help decide on, and take, any necessary corrective action (including action to 
prevent reoccurrence) in the event of any complaint or defect report 
Document owners are required to ensure that all aspects of documentation and records 
management specified in form of SOPs. All associates have the responsibility of ensuring 
that all GMP activities are performed according to the official SOPs; any deviations in 
procedure are reported to their supervisor and are adequately documented. 
There are various types of procedures that a GMP facility can follow. Given below is a list of 
the most common types of documents, along with a brief description of each. 
Site Master File: A document describing the GMP related activities of the manufacturer. 
Quality Manual: A global company document that describes, in paragraph form, the 
regulations and/or parts of the regulations that the company is required to follow. 
Policies: Documents that describe in general terms, and not with step-by-step instructions, 
how specific GMP aspects (such as security, documentation, health, and responsibilities) 
will be implemented. 
Standard Operating Procedures (SOPs): Step-by-step instructions for performing 
operational tasks or activities. 
Batch Records: These documents are typically used and completed by the manufacturing 
department. Batch records provide step-by-step instructions for production-related tasks 
and activities, besides including areas on the batch record itself for documenting such tasks. 
Test Methods: These documents are typically used and completed by the quality control 
(QC) department. Test methods provide step-by-step instructions for testing supplies, 
materials, products, and other production-related tasks and activities, e.g., environmental 
monitoring of the GMP facility. 
Logbooks: Bound collection of forms used to document activities. Typically, logbooks are 
used for documenting the operation, maintenance, and calibration of a piece of equipment. 
Logbooks are also used to record critical activities, e.g., monitoring of clean rooms, solution 
preparation, recording of deviation, change controls and its corrective action assignment. 
4.14.1 Hierarchical document system 
A company’s controlled GMP document system should be established in a hierarchical 
manner starting with the general regulations and working downward to more specific 
documents such as batch records (Figure 17). 
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Fig. 17. Document Hierarchical System (Source: Patel & Chotai, 2011) 
The regulations that a company is responsible for following (e.g., USFDA/EU 
GMP/ICH/WHO GMP/Schedule M, etc.) should be at the top of the document pyramid 
and should govern the directives of the sublevels. The level immediately beneath the 
regulations, level 1 document (e.g., the Quality Manual), should break the regulations into 
parts specific to those that the company is required to follow. These documents should 
establish overall principles and guidelines for how the company plans on developing, 
documenting, and implementing a GMP-compliant quality system.  
The next level, level 2, of documents in the hierarchical document pyramid should further 
break down the parts of the regulations into specific subjects or topics. These documents 
(e.g., Company Polices) should establish guidelines with which all subordinate level 
procedures must comply to ensure consistency across departments. SOPs should be the next 
level in the document hierarchy after company policy documents. These types of documents 
should provide specific step-by-step instructions for performing the operational tasks or 
activities that were talked about in the previous levels. Level 3 documents (i.e., SOPs) 
should be department specific or function specific. The last level of documents in a 
document hierarchical structure is level 4 documents. These documents are the most specific 
in nature, (e.g., batch record, test methods, validation procedures). They apply to a specific 
department, product, equipment, or process. Level 4 documents provide step-by-step 
Regulations (USFDA/EU GMP/WHO GMP) 
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instructions for production-related tasks and activities as well as provide a means for 
documenting such tasks using, for example, data sheets, forms, or batch records.  
The document hierarchy pyramid is one way of organizing a company’s documents. 
More/less levels may be added/subtracted to meet the company’s specific needs. Another 
way the required GMP documentation may be categorized as;  
Instructions (directions, or requirements) type: 
Specifications: Documents that list the requirements that a supply, material, or product 
must meet before being released for use or sale. The QC department will compare their test 
results to specifications to determine if they pass the test. 
Manufacturing Formulae, Processing, Packaging and Testing Instructions: Provide detail 
all the starting materials, equipment and computerized systems (if any) to be used and 
specify all processing, packaging, sampling and testing instructions. In process controls and 
process analytical technologies to be employed should be specified where relevant, together 
with acceptance criteria. 
Procedures: (Otherwise known as Standard Operating Procedures, or SOPs), give directions 
for performing certain operations. 
Protocols: Give instructions for performing and recording certain discreet operations. 
Technical Agreements: Are agreed between contract givers and acceptors for outsourced 
activities. 
Record/Report type: 
Records: Provide evidence of various actions taken to demonstrate compliance with 
instructions, e.g. activities, events, investigations, and in the case of manufactured batches a 
history of each batch of product, including its distribution. Records include the raw data 
which is used to generate other records. For electronic records regulated users should define 
which data are to be used as raw data. At least, all data on which quality decisions are based 
should be defined as raw data 
Certificates of Analysis: Provide a summary of testing results on samples of products or 
materials1 together with the evaluation for compliance to a stated specification. 
Reports: Document the conduct of particular exercises, projects or investigations, together 
with results, conclusions and recommendations (EudraLex, 2012). 
4.14.2 Manufacturing formula and processing instructions 
Approved, written Manufacturing Formula and Processing Instructions should exist for 
each product and batch size to be manufactured. 
The Manufacturing Formula should include: 
a. The name of the product, with a product reference code relating to its specification; 
b. A description of the pharmaceutical form, strength of the product and batch size; 
c. A list of all starting materials to be used, with the amount of each, described; mention 
should be made of any substance that may disappear in the course of processing; 
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d. A statement of the expected final yield with the acceptable limits, and of relevant 
intermediate yields, where applicable 
The Processing Instructions should include: 
a. A statement of the processing location and the principal equipment to be used; 
b. The methods, or reference to the methods, to be used for preparing the critical 
equipment (e.g. cleaning, assembling, calibrating, sterilizing); 
c. Checks that the equipment and work station are clear of previous products, documents 
or materials not required for the planned process, and that equipment is clean and 
suitable for use; 
d. Detailed stepwise processing instructions [e.g. checks on materials, pre-treatments, 
sequence for adding materials, critical process parameters (time, temp etc)]; 
e. The instructions for any in-process controls with their limits; 
f. Where necessary, the requirements for bulk storage of the products; including the 
container, labeling and special storage conditions where applicable; 
g. Any special precautions to be observed. 
Approved Packaging Instructions for each product, pack size and type should exist. These 
should include, or have a reference to, the following: 
a. Name of the product; including the batch number of bulk and finished product 
b. Description of its pharmaceutical form, and strength where applicable; 
c. The pack size expressed in terms of the number, weight or volume of the product in the 
final container; 
d. A complete list of all the packaging materials required, including quantities, sizes and 
types, with the code or reference number relating to the specifications of each 
packaging material; 
e. Where appropriate, an example or reproduction of the relevant printed packaging 
materials, and specimens indicating where to apply batch number references, and shelf 
life of the product; 
f. Checks that the equipment and work station are clear of previous products, documents 
or materials not required for the planned packaging operations (line clearance), and 
that equipment is clean and suitable for use. 
g. Special precautions to be observed, including a careful examination of the area and 
equipment in order to ascertain the line clearance before operations begin; 
h. A description of the packaging operation, including any significant subsidiary 
operations, and equipment to be used; 
i. Details of in-process controls with instructions for sampling and acceptance limits. 
4.14.3 Batch processing record 
A Batch Processing Record should be kept for each batch processed. It should be based on 
the relevant parts of the currently approved Manufacturing Formula and Processing 
Instructions, and should contain the following information: 
a. The name and batch number of the product; 
b. Dates and times of commencement, of significant intermediate stages and of completion 
of production; 
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c. Identification (initials) of the operator(s) who performed each significant step of the 
process and, where appropriate, the name of any person who checked these operations; 
d. The batch number and/or analytical control number as well as the quantities of each 
starting material actually weighed (including the batch number and amount of any 
recovered or reprocessed material added); 
e. Any relevant processing operation or event and major equipment used; 
f. A record of the in-process controls and the initials of the person(s) carrying them out, 
and the results obtained; 
g. The product yield obtained at different and pertinent stages of manufacture; 
h. Notes on special problems including details, with signed authorisation for any 
deviation from the Manufacturing Formula and Processing Instructions; 
i. Approval by the person responsible for the processing operations. 
4.14.4 Batch packaging record 
A Batch Packaging Record should be kept for each batch or part batch processed. It should 
be based on the relevant parts of the Packaging Instructions. The batch packaging record 
should contain the following information: 
a. The name and batch number of the product, 
b. The date(s) and times of the packaging operations; 
c. Identification (initials) of the operator(s) who performed each significant step of the 
process and, where appropriate, the name of any person who checked these operations;  
d. Records of checks for identity and conformity with the packaging instructions, 
including the results of in-process controls; 
e. Details of the packaging operations carried out, including references to equipment and 
the packaging lines used; 
f. Whenever possible, samples of printed packaging materials used, including specimens 
of the batch coding, expiry dating and any additional overprinting; 
g. Notes on any special problems or unusual events including details, with signed 
authorization for any deviation from the Packaging Instructions; 
h. The quantities and reference number or identification of all printed packaging materials 
and bulk product issued, used, destroyed or returned to stock and the quantities of 
obtained product, in order to provide for an adequate reconciliation. Where there are 
there are robust electronic controls in place during packaging there may be justification 
for not including this information 
i. Approval by the person responsible for the packaging operations 
4.15 Holding and distribution 
It cannot, indeed must not, be considered that concern for the quality of the products of the 
pharmaceutical industry may cease at the point where the product is filled, sealed, labeled, 
and approved or released by QC. True QA should extend right up to the point where the 
product is delivered to the ultimate consumer — the patient. Certainly, there will come a 
point where the influence that the manufacturer is able to exert will significantly decline. 
For example, the manufacturer can do little more than advise the dispensing pharmacist on 
the correct handling and storage of his drug products. Thereafter, the influence of the 
manufacturer becomes distinctly tenuous. Despite warnings and advice to patients given in 
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enclosure leaflets, it does seem that many patients neither handle nor take their medicines 
properly. That said, it is incumbent upon pharmaceutical manufacturers to ensure that 
having manufactured, packaged and labeled their products, the quality (i.e., “fitness”) of 
these product remains unimpaired for as far along the supply chain as they are able to exert 
influence. Manufacturers who distribute via external wholesale dealers should thus ensure 
that any such wholesale dealer is, indeed, in possession of an authorization to do so. 
Whatever their size and type, stores or warehouses all have a few things in common — they 
receive and take in goods or materials, they hold them (hopefully, safely and securely) for a 
while, and then they send them out again. Put very simply, even naively, its just a matter of 
goods in, goods hold, goods out. It may all seem simple, but it is worth pausing to think of 
how important it really is. Pharmaceutical products can do a lot of good — if they are of the 
right quality and are used properly. If they are incorrect, damaged, soiled, contaminated, 
wrongly labeled, have the wrong instructions for use, or have deteriorated, they could fail to 
have their desired good effects, and could be a danger to the health (or even the life) of the 
ultimate consumer or patient. 
The goods in phase provides an opportunity of checking that purchased materials or 
bought-in products, or finished products delivered from an internal packaging line, are 
correct and in good condition.  The goods inwards (or receiving) office will normally have a 
copy of the original purchase order, and the supplying company will usually send with the 
goods some form of delivery (or advice) note. The order, the delivery note, and the labeling 
on the goods should all be compared with each other to ensure that everything ties up. At 
the same time, the delivered goods should be checked for quantity, cleanliness, condition, 
and for any signs of damage or deterioration. If anything appears to be wrong, it should be 
reported by the goods-inwards staff immediately, so a decision can be made about accepting 
the delivery or sending the goods back. There also needs also to be a check on the batch 
number(s) of the delivery, to see if they match up with the batch numbers on the supplier’s 
delivery (or advice) note. When a delivery of a particular product or material consists of 
more than one supplier’s batch number, the different suppliers’ batches should be kept 
apart from each other, as far as recording, handling, and storing — and any sampling and 
testing that may be required — are concerned. 
It is usual to make a distinction between “returns” and “recalled products.” Returns are 
products returned from the market to a manufacturer’s warehouse, which are not 
specifically known to be seriously defective, but which have been sent back by a wholesale 
or retail customer because of overstocking, superficial damage, or some such similar reason. 
Recalled products are products that have been withdrawn from the market, at the request of 
the manufacturer, or the authorities, because of a known or suspected defect. 
4.15.1 Goods holding 
The goods hold stage is where it is necessary to ensure that the goods remain in good 
condition, and do not become harmed or damaged through incorrect or unsuitable storage 
conditions or bad handling. That is, it is important to ensure that quality goods are not 
reduced to rubbish. All goods must be stored in a clean, neat, orderly way, in conditions 
that will not affect their quality or cause them to deteriorate in any way. It is not just an 
issue of looking good. Untidy, scruffy stores are more difficult to run and control. They 
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increase the possibility of mix-up and confusion — mix-up of different types of goods, mix-
up of different batches (or lots), mix-up of goods of different status. It is very difficult to 
have effective stock rotation unless goods are stored in an orderly fashion.  
4.15.2 Goods out — distribution of products 
Goods out might well be the last chance of checking and ensuring that everything is in order 
before the goods leave a manufacturer’s hands, to the next step in the distribution chain, on 
their way to the consumer. It cannot be overstressed that people in stores and warehouses 
play a vital part in the QA of pharmaceutical products. They must be properly trained and 
fully aware of the significance of the job they are doing. Particular care is necessary in the 
picking and assembly of orders for dispatch. It is vitally important to ensure that the items 
picked are as specified in the customer’s order. But it goes further than that. This is perhaps 
the last chance to check that everything is OK. It is not only important to ensure that the 
right amounts of the right products, of the right strengths and sizes, are being picked for 
dispatch. It is also important that a watchful eye is kept open to check that the products 
being picked are in good condition, that they have been approved for distribution, and that 
they have not passed their expiry date (or shelf life). 
It is necessary to make, and keep, a record of each order that is dispatched, which shows: 
- Date of dispatch of goods 
- Customer’s name and address 
- Quantity, name, batch number, and expiry date of each product dispatched 
Distribution records must be constructed and procedures established to facilitate recall of 
defective product. A requisite of the system is approval and specific release of each lot of 
drug by the QC function before distribution can occur. This control of finished goods for 
shipment allows only those drugs into commerce that have been shown by testing to 
conform to appropriate requirements. The manufacturer must maintain records of all 
distribution transactions involving in process or finished goods. All records should be 
indexed by either the manufacturing batch lot number of the packaging control number as a 
means of accountability until the shipment passes from the direct control of the 
manufacturer. This type of indexing permits an efficient determination of the receiver of a 
lot to be recalled since only one shipment record need be examined. Depending on the 
marketing procedures of the individual company, distribution records may list shipments to 
consignees for packaging or labeling, or to an independent distributor, a wholesaler, a retail 
pharmacist, a physician, or possibly the ultimate consumer. All distribution records should 
be maintained for a minimum 3-year period after the distribution process for any control 
number has been completed. If expiration dating is used for a product, distribution records 
must be maintained at least for one year past the expiration date of the product. 
5. Conclusion 
GMP is a production and testing practice that helps to ensure in built quality product. Many 
countries have legislated that pharmaceutical companies must follow GMP procedures, and 
have created their own GMP guidelines that correspond with their legislation. Basic 
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concepts of all of these guidelines remain more or less similar to the ultimate goals of 
safeguarding the health of the patient as well as producing good quality medicines. 
The holder of a manufacturing authorization must manufacture quality medicines so as to 
ensure the products fit for the intended use, comply with the requirement of marketing 
authorization and place patients in safe with adequacy, quality and efficacy of the product. 
Quality objective can be achieved only through careful planning and implementation of QA 
system and practical implementation of GMP. The effective implementation of GMP 
requires extensive care and knowledge about the different components of GMP that should 
be incorporated form the inception of the manufacturing building and product development 
till the production. The compliance to QA/GMP does not happen by accident. The GMP 
compliance can be achieved as the result of careful planning and installation of quality 
system. The manufacturers remain responsible for product quality till the shelf life of the 
product. The effective implementation of GMP requires top level commitment and support 
from all level of employees of the organization and different external bodies such as 
government regulatory agencies, material suppliers, distributor, wholesalers, retailers, 
medical practitioners and the end users of the medicines.  
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